Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:belinostat
go back to main search page
Accession:CHEBI:61076 term browser browse the term
Definition:A hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity.
Synonyms:exact_synonym: (2E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide
 related_synonym: (2E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]acrylamide;   Formula=C15H14N2O4S;   InChI=1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+;   InChIKey=NCNRHFGMJRPRSK-MDZDMXLPSA-N;   N-Hydroxy-3-(3-(phenylsulfamoyl)phenyl)prop-2-enamide;   PXD101;   SMILES=ONC(=O)\\C=C\\c1cccc(c1)S(=O)(=O)Nc1ccccc1
 xref: CAS:414864-00-9;   KEGG:D08870
 xref_mesh: MESH:C487081
 xref: PMID:23382909;   PMID:23475695;   PMID:23644904;   PMID:24020452;   PMID:24369094;   PMID:24800886;   PMID:24918834;   PMID:25134672;   PMID:25189481;   PMID:25368524;   PMID:25389633;   PMID:25404094;   PMID:25433307;   PMID:25446119;   PMID:25483416;   PMID:25611313;   PMID:25673888;   Reaxys:10087570;   Wikipedia:Belinostat


show annotations for term's descendants           Sort by:
 
belinostat term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcc6 ATP binding cassette subfamily C member 6 decreases expression ISO belinostat results in decreased expression of ABCC6 mRNA CTD PMID:27188386 NCBI chr 1:101,954,786...102,013,252
Ensembl chr 1:101,959,540...102,013,243
JBrowse link
G Abl1 ABL proto-oncogene 1, non-receptor tyrosine kinase decreases expression ISO belinostat results in decreased expression of ABL1 mRNA CTD PMID:19606018 NCBI chr 3:10,041,820...10,145,076
Ensembl chr 3:10,041,826...10,144,388
JBrowse link
G Acacb acetyl-CoA carboxylase beta decreases expression ISO belinostat results in decreased expression of ACACB mRNA CTD PMID:27188386 NCBI chr12:48,127,149...48,238,969
Ensembl chr12:48,127,149...48,238,887
JBrowse link
G Acadsb acyl-CoA dehydrogenase, short/branched chain increases expression ISO belinostat results in increased expression of ACADSB mRNA CTD PMID:26272509 NCBI chr 1:201,981,362...202,022,771
Ensembl chr 1:201,981,357...202,021,008
JBrowse link
G Ackr3 atypical chemokine receptor 3 increases expression ISO belinostat results in increased expression of ACKR3 mRNA CTD PMID:27188386 NCBI chr 9:97,355,881...97,367,455
Ensembl chr 9:97,355,924...97,367,445
JBrowse link
G Acp5 acid phosphatase 5, tartrate resistant decreases expression ISO belinostat results in decreased expression of ACP5 mRNA CTD PMID:27188386 NCBI chr 8:23,142,733...23,149,067
Ensembl chr 8:23,142,734...23,148,396
JBrowse link
G Acsl5 acyl-CoA synthetase long-chain family member 5 decreases expression ISO belinostat results in decreased expression of ACSL5 mRNA CTD PMID:27188386 NCBI chr 1:276,240,703...276,290,012
Ensembl chr 1:276,240,703...276,290,008
JBrowse link
G Acsm3 acyl-CoA synthetase medium-chain family member 3 multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACSM3 mRNA CTD PMID:27188386 NCBI chr 1:189,514,504...189,541,233
Ensembl chr 1:189,514,553...189,541,224
JBrowse link
G Ada adenosine deaminase decreases expression
multiple interactions
ISO belinostat results in decreased expression of ADA mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADA mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 3:160,115,840...160,139,947
Ensembl chr 3:160,115,842...160,139,947
JBrowse link
G Adam12 ADAM metallopeptidase domain 12 decreases expression
multiple interactions
ISO belinostat results in decreased expression of ADAM12 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADAM12 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:205,951,840...206,286,294
Ensembl chr 1:205,956,342...206,282,575
JBrowse link
G Adamts15 ADAM metallopeptidase with thrombospondin type 1 motif, 15 multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS15 mRNA CTD PMID:27188386 NCBI chr 8:31,977,001...32,000,378
Ensembl chr 8:31,977,001...32,000,378
JBrowse link
G Adamts3 ADAM metallopeptidase with thrombospondin type 1, motif 3 decreases expression ISO belinostat results in decreased expression of ADAMTS3 mRNA CTD PMID:27188386 NCBI chr14:19,866,278...20,072,896
Ensembl chr14:19,866,408...20,070,994
JBrowse link
G Adcyap1 adenylate cyclase activating polypeptide 1 increases expression
multiple interactions
ISO belinostat results in increased expression of ADCYAP1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADCYAP1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 9:121,705,897...121,725,736
Ensembl chr 9:121,706,979...121,725,716
JBrowse link
G Adgrg1 adhesion G protein-coupled receptor G1 multiple interactions
decreases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRG1 mRNA
belinostat results in decreased expression of ADGRG1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr19:10,423,534...10,460,674
Ensembl chr19:10,423,501...10,460,674
JBrowse link
G Adgrl3 adhesion G protein-coupled receptor L3 decreases expression
multiple interactions
ISO belinostat results in decreased expression of ADGRL3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRL3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr14:28,362,176...29,226,085
Ensembl chr14:28,393,394...28,967,980
JBrowse link
G Adi1 acireductone dioxygenase 1 decreases expression ISO belinostat results in decreased expression of ADI1 mRNA CTD PMID:27188386 NCBI chr 6:47,940,211...47,947,173
Ensembl chr 6:47,940,183...47,947,230
JBrowse link
G Afp alpha-fetoprotein decreases expression ISO belinostat results in decreased expression of AFP mRNA CTD PMID:26272509 NCBI chr14:19,141,755...19,159,919
Ensembl chr14:19,141,755...19,159,923
JBrowse link
G Ak7 adenylate kinase 7 increases expression ISO belinostat results in increased expression of AK7 mRNA CTD PMID:27188386 NCBI chr 6:129,538,648...129,606,960
Ensembl chr 6:129,538,982...129,606,932
JBrowse link
G Akna AT-hook transcription factor decreases expression ISO belinostat results in decreased expression of AKNA mRNA CTD PMID:27188386 NCBI chr 5:79,184,087...79,232,370
Ensembl chr 5:79,184,088...79,222,687
JBrowse link
G Akt1 AKT serine/threonine kinase 1 increases phosphorylation ISO belinostat results in increased phosphorylation of AKT1 protein CTD PMID:23671600 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Aldob aldolase, fructose-bisphosphate B decreases expression ISO belinostat results in decreased expression of ALDOB mRNA CTD PMID:27188386 NCBI chr 5:64,805,772...64,818,813
Ensembl chr 5:64,805,773...64,818,824
JBrowse link
G Ampd3 adenosine monophosphate deaminase 3 decreases expression ISO belinostat results in decreased expression of AMPD3 mRNA CTD PMID:27188386 NCBI chr 1:175,585,301...175,630,479
Ensembl chr 1:175,586,097...175,630,467
JBrowse link
G Angpt1 angiopoietin 1 increases expression
multiple interactions
ISO belinostat results in increased expression of ANGPT1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANGPT1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 7:81,338,327...81,592,459
Ensembl chr 7:81,342,280...81,592,206
JBrowse link
G Angpt2 angiopoietin 2 decreases expression ISO belinostat results in decreased expression of ANGPT2 mRNA CTD PMID:27188386 NCBI chr16:75,966,480...76,016,147
Ensembl chr16:75,966,352...76,016,195
JBrowse link
G Anks1b ankyrin repeat and sterile alpha motif domain containing 1B multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANKS1B mRNA CTD PMID:27188386 NCBI chr 7:30,507,135...31,684,604
Ensembl chr 7:30,699,476...31,681,182
JBrowse link
G Ano3 anoctamin 3 increases expression
multiple interactions
ISO belinostat results in increased expression of ANO3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANO3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 3:101,843,516...102,203,368
Ensembl chr 3:101,840,630...102,151,489
JBrowse link
G Anxa2 annexin A2 increases expression
multiple interactions
ISO belinostat results in increased expression of ANXA2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 8:75,687,134...75,723,589
Ensembl chr 8:75,687,100...75,723,594
JBrowse link
G Anxa4 annexin A4 decreases expression ISO belinostat results in decreased expression of ANXA4 mRNA CTD PMID:27188386 NCBI chr 4:118,538,775...118,595,591
Ensembl chr 4:118,538,777...118,595,580
JBrowse link
G Aox1 aldehyde oxidase 1 decreases expression ISO belinostat results in decreased expression of AOX1 mRNA CTD PMID:27188386 NCBI chr 9:64,929,682...65,007,872
Ensembl chr 9:64,929,721...65,007,870
JBrowse link
G Ap5m1 adaptor related protein complex 5 subunit mu 1 increases expression ISO belinostat results in increased expression of AP5M1 mRNA CTD PMID:26272509 NCBI chr15:25,933,483...25,955,745
Ensembl chr15:25,933,483...25,955,745
JBrowse link
G Apoc1 apolipoprotein C1 decreases expression ISO belinostat results in decreased expression of APOC1 mRNA CTD PMID:27188386 NCBI chr 1:80,606,638...80,609,921
Ensembl chr 1:80,606,638...80,609,921
JBrowse link
G Arap3 ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 3 decreases expression ISO belinostat results in decreased expression of ARAP3 mRNA CTD PMID:27188386 NCBI chr18:31,112,083...31,138,142
Ensembl chr18:31,112,623...31,136,200
JBrowse link
G Arhgap24 Rho GTPase activating protein 24 increases expression
multiple interactions
ISO belinostat results in increased expression of ARHGAP24 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP24 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr14:8,383,211...8,600,526
Ensembl chr14:8,383,214...8,600,512
JBrowse link
G Arhgef37 Rho guanine nucleotide exchange factor 37 decreases expression
multiple interactions
ISO belinostat results in decreased expression of ARHGEF37 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGEF37 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr18:56,817,986...56,871,159
Ensembl chr18:56,817,988...56,870,839
JBrowse link
G Arhgef4 Rho guanine nucleotide exchange factor 4 decreases expression ISO belinostat results in decreased expression of ARHGEF4 mRNA CTD PMID:27188386 NCBI chr 9:41,160,562...41,305,015
Ensembl chr 9:41,295,909...41,302,501
JBrowse link
G Arnt2 aryl hydrocarbon receptor nuclear translocator 2 multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARNT2 mRNA CTD PMID:27188386 NCBI chr 1:146,399,217...146,556,437
Ensembl chr 1:146,399,217...146,556,171
JBrowse link
G Arrb1 arrestin, beta 1 increases expression
multiple interactions
ISO belinostat results in increased expression of ARRB1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARRB1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:164,502,099...164,573,947
Ensembl chr 1:164,502,389...164,593,139
JBrowse link
G Asgr1 asialoglycoprotein receptor 1 decreases expression ISO belinostat results in decreased expression of ASGR1 mRNA CTD PMID:27188386 NCBI chr10:56,662,188...56,666,086
Ensembl chr10:56,662,242...56,666,086
JBrowse link
G Asns asparagine synthetase (glutamine-hydrolyzing) decreases expression ISO belinostat results in decreased expression of ASNS mRNA CTD PMID:27188386 NCBI chr 4:33,742,876...33,761,106
Ensembl chr 4:33,743,364...33,761,163
JBrowse link
G Astn1 astrotactin 1 decreases expression ISO belinostat results in decreased expression of ASTN1 mRNA CTD PMID:26272509 NCBI chr13:76,054,965...76,370,674
Ensembl chr13:76,055,410...76,370,674
JBrowse link
G Atp8b1 ATPase phospholipid transporting 8B1 increases expression
multiple interactions
ISO belinostat results in increased expression of ATP8B1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP8B1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr18:60,013,388...60,152,920
Ensembl chr18:60,013,382...60,095,354
JBrowse link
G Aurka aurora kinase A decreases expression
decreases activity
ISO belinostat results in decreased expression of AURKA mRNA; belinostat results in decreased expression of AURKA protein
belinostat results in decreased activity of AURKA protein
CTD PMID:19606018 NCBI chr 3:170,364,177...170,380,278
Ensembl chr 3:170,364,181...170,378,210
JBrowse link
G Aurkb aurora kinase B decreases activity
decreases expression
ISO belinostat results in decreased activity of AURKB protein
belinostat results in decreased expression of AURKB mRNA; belinostat results in decreased expression of AURKB protein
CTD PMID:19606018 NCBI chr10:55,625,860...55,632,399
Ensembl chr10:55,626,741...55,634,991
JBrowse link
G Aven apoptosis and caspase activation inhibitor decreases expression ISO belinostat results in decreased expression of AVEN mRNA CTD PMID:27188386 NCBI chr 3:103,980,612...104,117,193
Ensembl chr 3:104,042,168...104,117,192
JBrowse link
G B3galnt1 beta-1,3-N-acetylgalactosaminyltransferase 1 (globoside blood group) decreases expression ISO belinostat results in decreased expression of B3GALNT1 mRNA CTD PMID:27188386 NCBI chr 2:166,226,736...166,255,978
Ensembl chr 2:166,226,754...166,255,302
JBrowse link
G B3gnt5 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 5 decreases expression
multiple interactions
ISO belinostat results in decreased expression of B3GNT5 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of B3GNT5 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr11:84,919,055...84,931,160
Ensembl chr11:84,919,066...84,931,160
JBrowse link
G Bag2 BAG cochaperone 2 multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAG2 mRNA
belinostat results in increased expression of BAG2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 9:38,456,487...38,467,120
Ensembl chr 9:38,456,468...38,467,118
JBrowse link
G Bambi BMP and activin membrane-bound inhibitor multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAMBI mRNA CTD PMID:27188386 NCBI chr17:56,905,419...56,909,675
Ensembl chr17:56,905,112...56,909,992
JBrowse link
G Bbs9 Bardet-Biedl syndrome 9 increases expression
multiple interactions
ISO belinostat results in increased expression of BBS9 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BBS9 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 8:23,491,929...24,074,524
Ensembl chr 8:23,492,621...24,074,536
Ensembl chr 8:23,492,621...24,074,536
JBrowse link
G Bcl11a BAF chromatin remodeling complex subunit BCL11A increases expression
multiple interactions
ISO belinostat results in increased expression of BCL11A mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BCL11A mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr14:108,826,717...108,921,197
Ensembl chr14:108,826,831...108,921,669
JBrowse link
G Bcl2 BCL2, apoptosis regulator decreases expression
multiple interactions
ISO belinostat results in decreased expression of BCL2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Bcl2l11 BCL2 like 11 increases expression ISO belinostat results in increased expression of BCL2L11 protein CTD PMID:18223231 NCBI chr 3:120,726,906...120,764,192
Ensembl chr 3:120,726,906...120,764,192
JBrowse link
G Bclaf1 BCL2-associated transcription factor 1 decreases expression ISO belinostat results in decreased expression of BCLAF1 mRNA CTD PMID:19606018 NCBI chr 1:15,799,753...15,828,838
Ensembl chr 1:15,782,477...15,860,624
JBrowse link
G Bfsp1 beaded filament structural protein 1 decreases expression ISO belinostat results in decreased expression of BFSP1 mRNA CTD PMID:27188386 NCBI chr 3:137,935,345...137,992,652
Ensembl chr 3:137,935,345...137,969,658
JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 decreases expression ISO belinostat results in decreased expression of BIRC5 mRNA CTD PMID:19606018 NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
JBrowse link
G Bmp5 bone morphogenetic protein 5 multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP5 mRNA
belinostat results in increased expression of BMP5 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 8:82,669,466...82,950,273
Ensembl chr 8:82,878,941...82,950,273
JBrowse link
G Bmper BMP-binding endothelial regulator increases expression
multiple interactions
ISO belinostat results in increased expression of BMPER mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMPER mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 8:24,369,916...24,615,484
Ensembl chr 8:24,369,916...24,615,479
JBrowse link
G Bmpr1b bone morphogenetic protein receptor type 1B decreases expression ISO belinostat results in decreased expression of BMPR1B mRNA CTD PMID:26272509 NCBI chr 2:247,392,195...247,662,026
Ensembl chr 2:247,403,920...247,446,882
JBrowse link
G Bnc2 basonuclin 2 multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BNC2 mRNA
belinostat results in increased expression of BNC2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 5:102,407,508...102,807,389
Ensembl chr 5:102,415,847...102,786,331
JBrowse link
G Borcs8 BLOC-1 related complex subunit 8 increases expression
multiple interactions
ISO belinostat results in increased expression of BORCS8 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BORCS8 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr16:21,022,500...21,029,163
Ensembl chr16:21,023,996...21,029,134
JBrowse link
G Bspry B-box and SPRY domain containing multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BSPRY mRNA CTD PMID:27188386 NCBI chr 5:78,334,284...78,356,462
Ensembl chr 5:78,334,284...78,356,460
JBrowse link
G Ca4 carbonic anhydrase 4 decreases expression ISO belinostat results in decreased expression of CA4 mRNA CTD PMID:27188386 NCBI chr10:72,272,286...72,281,069
Ensembl chr10:72,272,248...72,281,067
JBrowse link
G Cables1 Cdk5 and Abl enzyme substrate 1 decreases expression ISO belinostat results in decreased expression of CABLES1 mRNA CTD PMID:27188386 NCBI chr18:3,317,724...3,421,721
Ensembl chr18:3,317,724...3,421,721
JBrowse link
G Cad carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase decreases expression ISO belinostat results in decreased expression of CAD mRNA CTD PMID:19606018 NCBI chr 6:26,657,507...26,680,459
Ensembl chr 6:26,657,780...26,680,284
JBrowse link
G Calb1 calbindin 1 increases expression ISO belinostat results in increased expression of CALB1 mRNA CTD PMID:26272509 NCBI chr 5:29,538,380...29,562,774
Ensembl chr 5:29,538,380...29,562,773
JBrowse link
G Calhm6 calcium homeostasis modulator family member 6 decreases expression ISO belinostat results in decreased expression of CALHM6 mRNA CTD PMID:27188386 NCBI chr20:27,681,138...27,683,580
Ensembl chr20:27,681,036...27,682,861
JBrowse link
G Calml4 calmodulin-like 4 decreases expression
multiple interactions
ISO belinostat results in decreased expression of CALML4 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CALML4 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 8:67,753,279...67,765,359
Ensembl chr 8:67,753,279...67,765,358
JBrowse link
G Caprin1 cell cycle associated protein 1 decreases expression ISO belinostat results in decreased expression of CAPRIN1 mRNA CTD PMID:27188386 NCBI chr 3:93,701,830...93,789,580
Ensembl chr 3:93,702,487...93,789,617
JBrowse link
G Card10 caspase recruitment domain family, member 10 decreases expression ISO belinostat results in decreased expression of CARD10 mRNA CTD PMID:27188386 NCBI chr 7:119,998,639...120,028,632
Ensembl chr 7:119,999,472...120,027,026
JBrowse link
G Casp3 caspase 3 multiple interactions
increases cleavage
ISO Bortezomib promotes the reaction [belinostat results in increased cleavage of CASP3 protein] CTD PMID:18223231 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Casp8 caspase 8 increases expression
multiple interactions
ISO belinostat results in increased expression of CASP8 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CASP8 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
JBrowse link
G Casp9 caspase 9 increases cleavage
multiple interactions
ISO belinostat results in increased cleavage of CASP9 protein
Bortezomib promotes the reaction [belinostat results in increased cleavage of CASP9 protein]
CTD PMID:18223231 NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
JBrowse link
G Ccdc189 coiled-coil domain containing 189 increases expression ISO belinostat results in increased expression of CCDC189 mRNA CTD PMID:27188386 NCBI chr 1:199,032,105...199,037,267
Ensembl chr 1:199,032,105...199,037,267
JBrowse link
G Ccdc34 coiled-coil domain containing 34 increases expression ISO belinostat results in increased expression of CCDC34 mRNA CTD PMID:27188386 NCBI chr 3:101,156,212...101,191,363
Ensembl chr 3:101,156,212...101,191,363
JBrowse link
G Ccdc69 coiled-coil domain containing 69 increases expression
multiple interactions
ISO belinostat results in increased expression of CCDC69 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCDC69 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr10:40,392,459...40,419,567
Ensembl chr10:40,392,460...40,419,054
JBrowse link
G Cckbr cholecystokinin B receptor decreases expression
multiple interactions
ISO belinostat results in decreased expression of CCKBR mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCKBR mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:170,262,218...170,272,298
Ensembl chr 1:170,262,156...170,272,298
JBrowse link
G Ccl26 C-C motif chemokine ligand 26 increases expression
multiple interactions
ISO belinostat results in increased expression of CCL26 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCL26 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr12:24,157,182...24,161,870
Ensembl chr12:24,158,766...24,161,869
JBrowse link
G Ccn1 cellular communication network factor 1 increases expression ISO belinostat results in increased expression of CCN1 mRNA CTD PMID:23671600 NCBI chr 2:251,529,354...251,532,312
Ensembl chr 2:251,529,354...251,532,312
JBrowse link
G Ccn2 cellular communication network factor 2 increases expression ISO belinostat results in increased expression of CCN2 mRNA CTD PMID:19606018, PMID:23671600 NCBI chr 1:21,851,657...21,854,773
Ensembl chr 1:21,851,660...21,854,773
JBrowse link
G Ccna2 cyclin A2 decreases expression ISO belinostat results in decreased expression of CCNA2 mRNA CTD PMID:19606018 NCBI chr 2:123,274,727...123,282,266
Ensembl chr 2:123,275,881...123,282,214
JBrowse link
G Ccnb1 cyclin B1 decreases expression ISO belinostat results in decreased expression of CCNB1 mRNA CTD PMID:19606018 NCBI chr 2:30,782,133...30,791,106
Ensembl chr 2:30,783,915...30,791,221
JBrowse link
G Ccnd2 cyclin D2 decreases expression
multiple interactions
ISO belinostat results in decreased expression of CCND2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCND2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 4:159,674,885...159,697,207
Ensembl chr 4:159,674,885...159,697,207
JBrowse link
G Cd24 CD24 molecule multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD24 mRNA
belinostat results in increased expression of CD24 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr20:48,335,540...48,340,847
Ensembl chr20:48,335,540...48,340,846
JBrowse link
G Cd9 CD9 molecule increases expression
multiple interactions
ISO belinostat results in increased expression of CD9 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD9 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 4:157,977,163...158,010,091
Ensembl chr 4:157,977,162...158,010,166
JBrowse link
G Cdc25b cell division cycle 25B decreases expression ISO belinostat results in decreased expression of CDC25B mRNA CTD PMID:19606018 NCBI chr 3:123,731,539...123,741,696
Ensembl chr 3:123,731,539...123,741,339
JBrowse link
G Cdc25c cell division cycle 25C decreases expression ISO belinostat results in decreased expression of CDC25C mRNA CTD PMID:29733868 NCBI chr18:27,528,768...27,550,316
Ensembl chr18:27,528,354...27,550,224
JBrowse link
G Cdh1 cadherin 1 increases expression
multiple interactions
ISO belinostat results in increased expression of CDH1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr19:38,768,467...38,838,395
Ensembl chr19:38,768,467...38,838,395
JBrowse link
G Cdh18 cadherin 18 increases expression ISO belinostat results in increased expression of CDH18 mRNA CTD PMID:26272509 NCBI chr 2:73,651,408...74,693,342
Ensembl chr 2:74,360,622...74,693,341
JBrowse link
G Cdh3 cadherin 3 increases expression
multiple interactions
ISO belinostat results in increased expression of CDH3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr19:38,668,957...38,719,801
Ensembl chr19:38,669,230...38,719,677
JBrowse link
G Cdh9 cadherin 9 decreases expression
increases expression
ISO belinostat results in decreased expression of CDH9 mRNA
belinostat results in increased expression of CDH9 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 2:66,938,796...67,078,897
Ensembl chr 2:66,940,057...67,078,784
JBrowse link
G Cdk1 cyclin-dependent kinase 1 decreases expression ISO belinostat results in decreased expression of CDK1 mRNA CTD PMID:19606018 NCBI chr20:20,576,341...20,591,510
Ensembl chr20:20,576,377...20,591,549
JBrowse link
G Cdk4 cyclin-dependent kinase 4 decreases expression ISO belinostat results in decreased expression of CDK4 mRNA CTD PMID:19606018 NCBI chr 7:70,345,971...70,352,689
Ensembl chr 7:70,349,863...70,352,418
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A multiple interactions
increases expression
ISO belinostat promotes the reaction [decitabine results in increased expression of CDKN1A mRNA]; belinostat promotes the reaction [decitabine results in increased expression of CDKN1A protein]
belinostat results in increased expression of CDKN1A mRNA; belinostat results in increased expression of CDKN1A protein
CTD PMID:19234609, PMID:19606018 NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
JBrowse link
G Cdkn2a cyclin-dependent kinase inhibitor 2A decreases expression ISO belinostat results in decreased expression of CDKN2A mRNA CTD PMID:19606018 NCBI chr 5:107,823,323...107,832,405
Ensembl chr 5:107,823,330...107,841,175
JBrowse link
G Cdx4 caudal type homeo box 4 decreases expression ISO belinostat results in decreased expression of CDX4 mRNA CTD PMID:27188386 NCBI chr  X:74,165,172...74,173,758
Ensembl chr  X:74,165,187...74,173,347
JBrowse link
G Cep126 centrosomal protein 126 increases expression
multiple interactions
ISO belinostat results in increased expression of CEP126 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEP126 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 8:6,237,838...6,305,127
Ensembl chr 8:6,255,850...6,305,033
JBrowse link
G Cep85l centrosomal protein 85-like increases expression
multiple interactions
ISO belinostat results in increased expression of CEP85L mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEP85L mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr20:34,574,043...34,743,142
Ensembl chr20:34,575,950...34,684,418
JBrowse link
G Cfap20dc CFAP20 domain containing increases expression ISO belinostat results in increased expression of CFAP20DC mRNA CTD PMID:27188386 NCBI chr15:17,664,838...17,918,216
Ensembl chr15:17,775,692...17,924,302
JBrowse link
G Cftr CF transmembrane conductance regulator decreases expression ISO belinostat results in decreased expression of CFTR mRNA CTD PMID:27188386 NCBI chr 4:42,693,263...42,860,679
Ensembl chr 4:42,692,836...42,860,676
JBrowse link
G Chga chromogranin A increases expression
multiple interactions
ISO belinostat results in increased expression of CHGA mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHGA mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 6:126,434,226...126,445,569
Ensembl chr 6:126,434,226...126,445,568
JBrowse link
G Chodl chondrolectin multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHODL mRNA
belinostat results in increased expression of CHODL mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr11:17,537,980...17,560,305
Ensembl chr11:17,538,063...17,560,296
JBrowse link
G Chrm3 cholinergic receptor, muscarinic 3 increases expression
multiple interactions
ISO belinostat results in increased expression of CHRM3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHRM3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr17:63,990,599...64,463,222
Ensembl chr17:63,990,599...63,994,169
JBrowse link
G Chrna3 cholinergic receptor nicotinic alpha 3 subunit increases expression
multiple interactions
ISO belinostat results in increased expression of CHRNA3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHRNA3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 8:59,594,007...59,607,122
Ensembl chr 8:59,592,403...59,607,275
JBrowse link
G Chst15 carbohydrate sulfotransferase 15 increases expression ISO belinostat results in increased expression of CHST15 mRNA CTD PMID:27188386 NCBI chr 1:204,243,396...204,328,960
Ensembl chr 1:204,245,645...204,322,544
JBrowse link
G Cldn7 claudin 7 multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN7 mRNA
belinostat results in increased expression of CLDN7 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr10:56,576,326...56,578,632
Ensembl chr10:56,576,428...56,578,626
JBrowse link
G Clrn1 clarin 1 increases expression ISO belinostat results in increased expression of CLRN1 mRNA CTD PMID:27188386 NCBI chr 2:149,049,925...149,088,787
Ensembl chr 2:149,049,925...149,088,787
JBrowse link
G Clrn3 clarin 3 decreases expression ISO belinostat results in decreased expression of CLRN3 mRNA CTD PMID:27188386 NCBI chr 1:207,750,627...207,766,250
Ensembl chr 1:207,750,223...207,811,008
JBrowse link
G Clu clusterin multiple interactions
increases expression
ISO belinostat promotes the reaction [decitabine results in increased expression of CLU mRNA]; belinostat promotes the reaction [decitabine results in increased expression of CLU protein]
belinostat results in increased expression of CLU mRNA; belinostat results in increased expression of CLU protein
CTD PMID:19234609, PMID:19606018 NCBI chr15:42,626,612...42,665,858
Ensembl chr15:42,640,146...42,665,857
JBrowse link
G Cmpk2 cytidine/uridine monophosphate kinase 2 decreases expression ISO belinostat results in decreased expression of CMPK2 mRNA CTD PMID:27188386 NCBI chr 6:45,683,242...45,694,824
Ensembl chr 6:45,683,234...45,694,822
JBrowse link
G Cnksr2 connector enhancer of kinase suppressor of Ras 2 multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNKSR2 mRNA CTD PMID:27188386 NCBI chr  X:39,711,001...39,953,860
Ensembl chr  X:39,711,201...39,951,847
JBrowse link
G Cnmd chondromodulin increases expression
multiple interactions
ISO belinostat results in increased expression of CNMD mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNMD mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr15:61,923,291...61,947,840
Ensembl chr15:61,923,299...61,947,764
JBrowse link
G Cntn1 contactin 1 increases expression
multiple interactions
ISO belinostat results in increased expression of CNTN1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNTN1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 7:133,290,606...133,588,314
Ensembl chr 7:133,400,485...133,586,677
JBrowse link
G Cntn3 contactin 3 decreases expression
multiple interactions
ISO belinostat results in decreased expression of CNTN3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTN3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 4:134,783,671...135,159,309
Ensembl chr 4:134,784,668...135,069,970
JBrowse link
G Cntnap4 contactin associated protein family member 4 decreases expression ISO belinostat results in decreased expression of CNTNAP4 mRNA CTD PMID:27188386 NCBI chr19:44,817,727...45,118,133
Ensembl chr19:44,908,905...45,117,309
JBrowse link
G Cobl cordon-bleu WH2 repeat protein multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COBL mRNA CTD PMID:27188386 NCBI chr14:92,341,949...92,497,169
Ensembl chr14:92,342,957...92,577,936
JBrowse link
G Coch cochlin decreases expression ISO belinostat results in decreased expression of COCH mRNA CTD PMID:27188386 NCBI chr 6:72,359,702...72,373,710
Ensembl chr 6:72,359,791...72,373,695
JBrowse link
G Col1a2 collagen type I alpha 2 chain multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL1A2 mRNA
belinostat results in increased expression of COL1A2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 4:31,534,225...31,569,152
Ensembl chr 4:31,534,225...31,569,151
JBrowse link
G Col26a1 collagen type XXVI alpha 1 chain decreases expression ISO belinostat results in decreased expression of COL26A1 mRNA CTD PMID:27188386 NCBI chr12:22,834,866...22,980,603
Ensembl chr12:22,835,019...22,980,603
JBrowse link
G Col6a6 collagen type VI alpha 6 chain decreases expression ISO belinostat results in decreased expression of COL6A6 mRNA CTD PMID:27188386 NCBI chr 8:114,352,130...114,449,993
Ensembl chr 8:114,353,825...114,449,956
JBrowse link
G Colec12 collectin sub-family member 12 increases expression ISO belinostat results in increased expression of COLEC12 mRNA CTD PMID:26272509 NCBI chr18:867,048...1,054,047
Ensembl chr18:867,048...1,052,606
JBrowse link
G Colgalt2 collagen beta(1-O)galactosyltransferase 2 decreases expression
multiple interactions
ISO belinostat results in decreased expression of COLGALT2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of COLGALT2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr13:69,797,558...69,902,916
Ensembl chr13:69,797,880...69,901,170
JBrowse link
G Comtd1 catechol-O-methyltransferase domain containing 1 multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COMTD1 mRNA
belinostat results in increased expression of COMTD1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr15:2,631,529...2,634,640
Ensembl chr15:2,631,529...2,634,640
JBrowse link
G Cpne2 copine 2 decreases expression ISO belinostat results in decreased expression of CPNE2 mRNA CTD PMID:27188386 NCBI chr19:10,860,963...10,898,970
Ensembl chr19:10,861,406...10,884,047
JBrowse link
G Cpne4 copine 4 multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPNE4 mRNA
belinostat results in increased expression of CPNE4 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 8:113,105,814...113,586,429
Ensembl chr 8:113,105,814...113,586,418
JBrowse link
G Cr1l complement C3b/C4b receptor 1 like increases expression
multiple interactions
ISO belinostat results in increased expression of CR1L mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CR1L mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr13:113,824,886...113,872,097
Ensembl chr13:113,824,892...113,872,097
JBrowse link
G Crb1 crumbs cell polarity complex component 1 increases expression ISO belinostat results in increased expression of CRB1 mRNA CTD PMID:27188386 NCBI chr13:56,270,519...56,462,893
Ensembl chr13:56,270,781...56,462,834
JBrowse link
G Crip1 cysteine rich protein 1 multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRIP1 mRNA
belinostat results in increased expression of CRIP1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 6:137,959,171...137,967,042
Ensembl chr 6:137,959,171...137,967,042
JBrowse link
G Cryba4 crystallin, beta A4 decreases expression
multiple interactions
ISO belinostat results in decreased expression of CRYBA4 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CRYBA4 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr12:50,407,843...50,414,434
Ensembl chr12:50,407,843...50,414,432
JBrowse link
G Crybg1 crystallin beta-gamma domain containing 1 increases expression
multiple interactions
ISO belinostat results in increased expression of CRYBG1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRYBG1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr20:48,927,942...49,123,724
Ensembl chr20:48,927,914...48,969,499
JBrowse link
G Cthrc1 collagen triple helix repeat containing 1 increases expression
multiple interactions
ISO belinostat results in increased expression of CTHRC1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTHRC1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 7:77,966,722...77,977,004
Ensembl chr 7:77,966,722...77,977,004
JBrowse link
G Ctps1 CTP synthase 1 decreases expression ISO belinostat results in decreased expression of CTPS1 mRNA CTD PMID:19606018 NCBI chr 5:139,475,934...139,505,065
Ensembl chr 5:139,475,934...139,505,065
JBrowse link
G Ctsk cathepsin K decreases expression ISO belinostat results in decreased expression of CTSK mRNA CTD PMID:27188386 NCBI chr 2:196,655,469...196,666,447
Ensembl chr 2:196,655,469...196,666,446
JBrowse link
G Ctso cathepsin O decreases expression ISO belinostat results in decreased expression of CTSO mRNA CTD PMID:27188386 NCBI chr 2:180,857,178...180,881,677 JBrowse link
G Cxcl12 C-X-C motif chemokine ligand 12 increases expression
multiple interactions
decreases expression
ISO belinostat results in increased expression of CXCL12 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXCL12 mRNA
belinostat results in decreased expression of CXCL12 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 4:149,261,044...149,273,891
Ensembl chr 4:149,261,044...149,273,891
JBrowse link
G Cxcl14 C-X-C motif chemokine ligand 14 increases expression ISO belinostat results in increased expression of CXCL14 mRNA CTD PMID:26272509 NCBI chr17:9,109,731...9,117,754
Ensembl chr17:9,109,731...9,117,750
JBrowse link
G Cyfip1 cytoplasmic FMR1 interacting protein 1 decreases expression ISO belinostat results in decreased expression of CYFIP1 mRNA CTD PMID:27188386 NCBI chr 1:114,258,773...114,347,138
Ensembl chr 1:114,258,719...114,347,137
JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 increases expression ISO belinostat results in increased expression of CYP1B1 mRNA CTD PMID:26272509 NCBI chr 6:2,308,179...2,316,739
Ensembl chr 6:2,307,808...2,316,722
JBrowse link
G Cyp26a1 cytochrome P450, family 26, subfamily a, polypeptide 1 increases expression ISO belinostat results in increased expression of CYP26A1 mRNA CTD PMID:26272509 NCBI chr 1:256,382,861...256,386,729
Ensembl chr 1:256,382,791...256,386,729
JBrowse link
G Cyp39a1 cytochrome P450, family 39, subfamily a, polypeptide 1 increases expression ISO belinostat results in increased expression of CYP39A1 mRNA CTD PMID:27188386 NCBI chr 9:19,804,079...19,880,346
Ensembl chr 9:19,804,079...19,880,346
JBrowse link
G Cyth1 cytohesin 1 decreases expression ISO belinostat results in decreased expression of CYTH1 mRNA CTD PMID:27188386 NCBI chr10:107,197,983...107,281,285
Ensembl chr10:107,197,989...107,281,235
JBrowse link
G Dact1 dishevelled-binding antagonist of beta-catenin 1 increases expression
multiple interactions
ISO belinostat results in increased expression of DACT1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DACT1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 6:93,740,440...93,751,003
Ensembl chr 6:93,740,586...93,749,809
JBrowse link
G Dazl deleted in azoospermia-like multiple interactions
decreases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DAZL mRNA
belinostat results in decreased expression of DAZL mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 9:12,633,983...12,651,017
Ensembl chr 9:12,633,990...12,650,938
JBrowse link
G Dcaf7 DDB1 and CUL4 associated factor 7 increases expression ISO belinostat results in increased expression of DCAF7 mRNA CTD PMID:27188386 NCBI chr10:94,231,585...94,254,046
Ensembl chr10:94,231,585...94,254,046
JBrowse link
G Dcc DCC netrin 1 receptor multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCC mRNA CTD PMID:27188386 NCBI chr18:66,518,213...67,629,801
Ensembl chr18:66,523,120...67,224,566
JBrowse link
G Dcdc2 doublecortin domain containing 2 decreases expression ISO belinostat results in decreased expression of DCDC2 mRNA CTD PMID:27188386 NCBI chr17:41,838,201...42,031,265
Ensembl chr17:41,838,201...42,031,265
JBrowse link
G Ddb2 damage specific DNA binding protein 2 decreases expression ISO belinostat results in decreased expression of DDB2 mRNA CTD PMID:29733868 NCBI chr 3:80,030,437...80,052,984
Ensembl chr 3:80,030,437...80,052,953
JBrowse link
G Ddc dopa decarboxylase decreases expression ISO belinostat results in decreased expression of DDC mRNA CTD PMID:27188386 NCBI chr14:91,905,919...91,996,816
Ensembl chr14:91,905,919...91,996,774
JBrowse link
G Ddx21 DExD-box helicase 21 decreases expression ISO belinostat results in decreased expression of DDX21 mRNA CTD PMID:19606018 NCBI chr20:32,213,147...32,232,632
Ensembl chr20:32,213,148...32,232,632
JBrowse link
G Defb1 defensin beta 1 decreases expression ISO belinostat results in decreased expression of DEFB1 mRNA CTD PMID:27188386 NCBI chr16:75,294,385...75,309,127
Ensembl chr16:75,294,376...75,309,176
JBrowse link
G Dennd1a DENN domain containing 1A decreases expression
multiple interactions
ISO belinostat results in decreased expression of DENND1A mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND1A mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 3:22,061,120...22,501,502
Ensembl chr 3:22,058,400...22,500,765
JBrowse link
G Depdc7 DEP domain containing 7 increases expression
multiple interactions
ISO belinostat results in increased expression of DEPDC7 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DEPDC7 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 3:94,665,714...94,687,013
Ensembl chr 3:94,665,717...94,686,989
JBrowse link
G Deptor DEP domain containing MTOR-interacting protein increases expression
multiple interactions
ISO belinostat results in increased expression of DEPTOR mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DEPTOR mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 7:94,795,161...95,000,750
Ensembl chr 7:94,795,214...94,995,809
JBrowse link
G Dgki diacylglycerol kinase, iota multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DGKI mRNA CTD PMID:27188386 NCBI chr 4:64,365,115...64,831,473
Ensembl chr 4:64,374,342...64,831,473
JBrowse link
G Dhrs2 dehydrogenase/reductase 2 multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DHRS2 mRNA
belinostat results in increased expression of DHRS2 mRNA
CTD PMID:19606018, PMID:27188386 NCBI chr15:33,876,701...33,891,559
Ensembl chr15:33,885,106...33,891,539
JBrowse link
G Diaph2 diaphanous-related formin 2 increases expression
multiple interactions
ISO belinostat results in increased expression of DIAPH2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DIAPH2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr  X:99,722,910...100,363,228 JBrowse link
G Dio1 iodothyronine deiodinase 1 decreases expression ISO belinostat results in decreased expression of DIO1 mRNA CTD PMID:27188386 NCBI chr 5:126,894,837...126,911,532
Ensembl chr 5:126,895,286...126,911,520
JBrowse link
G Dkk1 dickkopf WNT signaling pathway inhibitor 1 increases expression ISO belinostat results in increased expression of DKK1 mRNA CTD PMID:26272509 NCBI chr 1:248,952,896...248,956,579
Ensembl chr 1:248,895,738...248,898,607
JBrowse link
G Dnajb1 DnaJ heat shock protein family (Hsp40) member B1 increases expression ISO belinostat results in increased expression of DNAJB1 mRNA CTD PMID:19606018 NCBI chr19:24,747,178...24,750,919
Ensembl chr19:24,747,178...24,750,919
JBrowse link
G Dner delta/notch-like EGF repeat containing increases expression
multiple interactions
ISO belinostat results in increased expression of DNER mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DNER mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 9:91,965,866...92,291,172
Ensembl chr 9:91,965,866...92,291,220
JBrowse link
G Dock10 dedicator of cytokinesis 10 decreases expression ISO belinostat results in decreased expression of DOCK10 mRNA CTD PMID:27188386 NCBI chr 9:86,424,638...86,571,854
NCBI chr 9:86,312,470...86,423,054
Ensembl chr 9:86,312,501...86,571,870
JBrowse link
G Dok5 docking protein 5 increases expression ISO belinostat results in increased expression of DOK5 mRNA CTD PMID:26272509 NCBI chr 3:168,345,116...168,482,445
Ensembl chr 3:168,345,152...168,482,441
JBrowse link
G Dppa5 developmental pluripotency associated 5 increases expression
multiple interactions
ISO belinostat results in increased expression of DPPA5 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DPPA5 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 8:85,711,560...85,713,313
Ensembl chr 8:85,711,795...85,712,647
Ensembl chr 7:85,711,795...85,712,647
Ensembl chr 3:85,711,795...85,712,647
JBrowse link
G Dtx3l deltex E3 ubiquitin ligase 3L decreases expression ISO belinostat results in decreased expression of DTX3L mRNA CTD PMID:27188386 NCBI chr11:67,758,093...67,767,623
NCBI chr11:67,768,542...67,772,428
Ensembl chr11:67,757,928...67,767,622
JBrowse link
G Dusp10 dual specificity phosphatase 10 increases expression ISO belinostat results in increased expression of DUSP10 mRNA CTD PMID:26272509 NCBI chr13:104,284,660...104,321,455
Ensembl chr13:104,284,660...104,321,455
JBrowse link
G Dusp9 dual specificity phosphatase 9 decreases expression ISO belinostat results in decreased expression of DUSP9 mRNA CTD PMID:27188386 NCBI chr  X:157,168,143...157,172,068
Ensembl chr  X:157,168,144...157,172,068
JBrowse link
G Dynlt5 dynein light chain Tctex-type 5 increases expression ISO belinostat results in increased expression of DYNLT5 mRNA CTD PMID:27188386 NCBI chr 5:122,498,892...122,522,110
Ensembl chr 5:122,508,388...122,521,245
JBrowse link
G E2f2 E2F transcription factor 2 decreases expression ISO belinostat results in decreased expression of E2F2 mRNA CTD PMID:26272509 NCBI chr 5:154,516,611...154,540,228
Ensembl chr 5:154,522,119...154,540,265
JBrowse link
G Eaf2 ELL associated factor 2 multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EAF2 mRNA CTD PMID:27188386 NCBI chr11:66,878,658...66,923,092
Ensembl chr11:66,878,658...66,923,092
JBrowse link
G Echdc2 enoyl CoA hydratase domain containing 2 decreases expression ISO belinostat results in decreased expression of ECHDC2 mRNA CTD PMID:27188386 NCBI chr 5:127,770,570...127,789,568
Ensembl chr 5:127,770,570...127,789,567
JBrowse link
G Edn1 endothelin 1 increases expression
multiple interactions
ISO belinostat results in increased expression of EDN1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDN1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr17:22,136,814...22,143,745
Ensembl chr17:22,137,324...22,143,324
JBrowse link
G Ednra endothelin receptor type A increases expression
multiple interactions
ISO belinostat results in increased expression of EDNRA mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRA mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr19:33,928,356...33,991,703
Ensembl chr19:33,928,356...33,991,703
JBrowse link
G Ednrb endothelin receptor type B multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRB mRNA
belinostat results in increased expression of EDNRB mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr15:88,004,775...88,036,354
Ensembl chr15:88,006,977...88,036,354
JBrowse link
G Eef1a1 eukaryotic translation elongation factor 1 alpha 1 affects expression ISO belinostat affects the expression of EEF1A1 mRNA CTD PMID:27015953 NCBI chr 8:85,838,594...85,841,816
Ensembl chr 8:85,838,869...85,840,818
JBrowse link
G Efcab2 EF-hand calcium binding domain 2 decreases expression ISO belinostat results in decreased expression of EFCAB2 mRNA CTD PMID:27188386 NCBI chr13:96,303,578...96,414,404
Ensembl chr13:96,303,703...96,414,404
JBrowse link
G Efna1 ephrin A1 multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EFNA1 mRNA
belinostat results in increased expression of EFNA1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 2:188,588,808...188,596,156
Ensembl chr 2:188,588,796...188,596,222
JBrowse link
G Egf epidermal growth factor multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EGF mRNA CTD PMID:27188386 NCBI chr 2:68,820,616...68,895,537 JBrowse link
G Eif4g2 eukaryotic translation initiation factor 4, gamma 2 decreases expression ISO belinostat results in decreased expression of EIF4G2 mRNA CTD PMID:19606018 NCBI chr 1:175,883,362...175,895,510
Ensembl chr 1:175,883,363...175,895,510
JBrowse link
G Elmod1 ELMO domain containing 1 increases expression
multiple interactions
ISO belinostat results in increased expression of ELMOD1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELMOD1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 8:58,486,078...58,542,884
Ensembl chr 8:58,486,078...58,542,844
JBrowse link
G Elovl2 ELOVL fatty acid elongase 2 decreases expression
multiple interactions
ISO belinostat results in decreased expression of ELOVL2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ELOVL2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr17:21,382,461...21,422,413
Ensembl chr17:21,382,455...21,422,407
JBrowse link
G Epb41l3 erythrocyte membrane protein band 4.1-like 3 increases expression
multiple interactions
ISO belinostat results in increased expression of EPB41L3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 9:117,314,935...117,666,408
Ensembl chr 9:117,538,009...117,666,410
JBrowse link
G Epb41l5 erythrocyte membrane protein band 4.1 like 5 increases expression ISO belinostat results in increased expression of EPB41L5 mRNA CTD PMID:26272509 NCBI chr13:35,622,472...35,673,449
Ensembl chr13:35,580,098...35,668,968
JBrowse link
G Epcam epithelial cell adhesion molecule increases expression ISO belinostat results in increased expression of EPCAM mRNA CTD PMID:26272509 NCBI chr 6:11,282,194...11,308,870
Ensembl chr 6:11,281,964...11,298,216
JBrowse link
G Epdr1 ependymin related 1 decreases expression ISO belinostat results in decreased expression of EPDR1 mRNA CTD PMID:27188386 NCBI chr17:47,397,558...47,422,183
Ensembl chr17:47,397,558...47,422,182
JBrowse link
G Epha1 Eph receptor A1 increases expression
multiple interactions
ISO belinostat results in increased expression of EPHA1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 4:71,749,100...71,763,681
Ensembl chr 4:71,749,242...71,763,679
JBrowse link
G Epha3 Eph receptor A3 increases expression ISO belinostat results in increased expression of EPHA3 mRNA CTD PMID:26272509 NCBI chr11:421,253...783,037
Ensembl chr11:421,135...782,954
JBrowse link
G Epha7 Eph receptor A7 increases expression ISO belinostat results in increased expression of EPHA7 mRNA CTD PMID:26272509 NCBI chr 5:43,602,744...43,761,198
Ensembl chr 5:43,603,043...43,757,549
JBrowse link
G Ephb2 Eph receptor B2 decreases expression
multiple interactions
ISO belinostat results in decreased expression of EPHB2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHB2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 5:155,024,478...155,143,539
Ensembl chr 5:155,022,493...155,204,456
JBrowse link
G Ermap erythroblast membrane associated protein (Scianna blood group) decreases expression ISO belinostat results in decreased expression of ERMAP mRNA CTD PMID:27188386 NCBI chr 5:138,227,168...138,240,509
Ensembl chr 5:138,227,855...138,239,306
JBrowse link
G Ets1 ETS proto-oncogene 1, transcription factor increases expression
multiple interactions
ISO belinostat results in increased expression of ETS1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ETS1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 8:33,756,634...33,879,625
Ensembl chr 8:33,816,386...33,879,625
JBrowse link
G Etv5 ETS variant transcription factor 5 decreases expression ISO belinostat results in decreased expression of ETV5 mRNA CTD PMID:27188386 NCBI chr11:82,194,657...82,252,145
Ensembl chr11:82,194,657...82,252,139
JBrowse link
G Exo1 exonuclease 1 decreases expression ISO belinostat results in decreased expression of EXO1 protein CTD PMID:29733868 NCBI chr13:93,936,989...93,962,749
Ensembl chr13:93,939,022...93,960,342
JBrowse link
G Ezh1 enhancer of zeste 1 polycomb repressive complex 2 subunit increases expression ISO belinostat results in increased expression of EZH1 mRNA CTD PMID:27188386 NCBI chr10:89,104,026...89,139,978
Ensembl chr10:89,104,027...89,130,339
JBrowse link
G F10 coagulation factor X decreases expression ISO belinostat results in decreased expression of F10 mRNA CTD PMID:27188386 NCBI chr16:81,803,169...81,822,476
Ensembl chr16:81,803,110...81,822,716
JBrowse link
G F13a1 coagulation factor XIII A1 chain increases expression ISO belinostat results in increased expression of F13A1 mRNA CTD PMID:27188386 NCBI chr17:28,504,650...28,680,015
Ensembl chr17:28,504,623...28,680,362
JBrowse link
G F2rl1 F2R like trypsin receptor 1 decreases expression
increases expression
multiple interactions
ISO belinostat results in decreased expression of F2RL1 mRNA
belinostat results in increased expression of F2RL1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of F2RL1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 2:25,222,324...25,235,275
Ensembl chr 2:25,222,328...25,235,275
JBrowse link
G Fabp1 fatty acid binding protein 1 decreases expression ISO belinostat results in decreased expression of FABP1 mRNA CTD PMID:27188386 NCBI chr 4:99,063,181...99,066,957
Ensembl chr 4:99,063,181...99,066,954
JBrowse link
G Fabp3 fatty acid binding protein 3 multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FABP3 mRNA CTD PMID:27188386 NCBI chr 5:148,528,854...148,535,597
Ensembl chr 5:148,528,725...148,535,565
JBrowse link
G Fam174b family with sequence similarity 174, member B decreases expression ISO belinostat results in decreased expression of FAM174B mRNA CTD PMID:27188386 NCBI chr 1:135,081,596...135,180,266
Ensembl chr 1:135,083,974...135,162,685
JBrowse link
G Fam222a family with sequence similarity 222, member A decreases expression
multiple interactions
ISO belinostat results in decreased expression of FAM222A mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM222A mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr12:47,742,449...47,793,534
Ensembl chr12:47,748,165...47,793,534
JBrowse link
G Fam43a family with sequence similarity 43, member A increases expression
multiple interactions
ISO belinostat results in increased expression of FAM43A mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM43A mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr11:73,676,601...73,679,003
Ensembl chr11:73,676,601...73,678,984
JBrowse link
G Fancg FA complementation group G decreases expression ISO belinostat results in decreased expression of FANCG mRNA CTD PMID:29733868 NCBI chr 5:58,448,060...58,456,416
Ensembl chr 5:58,448,822...58,455,819
JBrowse link
G Far2 fatty acyl CoA reductase 2 decreases expression ISO belinostat results in decreased expression of FAR2 mRNA CTD PMID:27188386 NCBI chr 4:182,446,400...182,563,485
Ensembl chr 4:182,483,194...182,565,436
JBrowse link
G Fbln1 fibulin 1 decreases expression
multiple interactions
ISO belinostat results in decreased expression of FBLN1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBLN1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 7:126,096,793...126,176,468
Ensembl chr 7:126,096,793...126,176,468
JBrowse link
G Fbln2 fibulin 2 decreases expression ISO belinostat results in decreased expression of FBLN2 mRNA CTD PMID:27188386 NCBI chr 4:122,835,237...122,895,127
Ensembl chr 4:122,835,436...122,895,121
JBrowse link
G Fbln7 fibulin 7 multiple interactions
decreases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBLN7 mRNA
belinostat results in decreased expression of FBLN7 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 3:121,407,981...121,441,660
Ensembl chr 3:121,408,146...121,440,787
JBrowse link
G Fbn1 fibrillin 1 decreases expression ISO belinostat results in decreased expression of FBN1 mRNA CTD PMID:27188386 NCBI chr 3:117,569,708...117,766,160
Ensembl chr 3:117,569,697...117,766,120
JBrowse link
G Fbxo43 F-box protein 43 decreases expression
multiple interactions
ISO belinostat results in decreased expression of FBXO43 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXO43 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 7:74,925,091...74,938,796
Ensembl chr 7:74,925,092...74,938,663
JBrowse link
G Fbxw4 F-box and WD repeat domain containing 4 decreases expression ISO belinostat results in decreased expression of FBXW4 mRNA CTD PMID:27188386 NCBI chr 1:265,318,526...265,420,503
Ensembl chr 1:265,318,526...265,420,503
JBrowse link
G Fgf4 fibroblast growth factor 4 increases expression
multiple interactions
ISO belinostat results in increased expression of FGF4 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGF4 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:218,024,537...218,029,539
Ensembl chr 1:218,025,810...218,027,220
JBrowse link
G Fgf9 fibroblast growth factor 9 multiple interactions
decreases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA
belinostat results in decreased expression of FGF9 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr15:38,341,657...38,386,945
Ensembl chr15:38,341,089...38,387,316
JBrowse link
G Flt1 Fms related receptor tyrosine kinase 1 increases expression
multiple interactions
ISO belinostat results in increased expression of FLT1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FLT1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr12:9,033,993...9,205,886
Ensembl chr12:9,034,308...9,205,905
JBrowse link
G Fmo5 flavin containing dimethylaniline monoxygenase 5 decreases expression ISO belinostat results in decreased expression of FMO5 mRNA CTD PMID:27188386 NCBI chr 2:199,796,870...199,823,927
Ensembl chr 2:199,796,881...199,823,927
JBrowse link
G Folr1 folate receptor alpha decreases expression ISO belinostat results in decreased expression of FOLR1 mRNA CTD PMID:27188386 NCBI chr 1:166,934,457...166,945,864
Ensembl chr 1:166,934,460...166,943,592
JBrowse link
G Foxc2 forkhead box C2 increases expression ISO belinostat results in increased expression of FOXC2 mRNA CTD PMID:26272509 NCBI chr19:53,044,379...53,047,081
Ensembl chr19:53,044,379...53,047,081
JBrowse link
G Foxd3 forkhead box D3 increases expression
multiple interactions
ISO belinostat results in increased expression of FOXD3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXD3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 5:118,346,283...118,349,120 JBrowse link
G Foxh1 forkhead box H1 increases expression
multiple interactions
ISO belinostat results in increased expression of FOXH1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXH1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 7:117,730,307...117,733,076
Ensembl chr 7:117,730,307...117,732,387
JBrowse link
G Foxo1 forkhead box O1 multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXO1 mRNA
belinostat results in increased expression of FOXO1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 2:141,451,234...141,527,016
Ensembl chr 2:141,451,234...141,527,016
JBrowse link
G Frem1 Fras1 related extracellular matrix 1 decreases expression ISO belinostat results in decreased expression of FREM1 mRNA CTD PMID:27188386 NCBI chr 5:101,018,009...101,166,794
Ensembl chr 5:101,020,448...101,166,651
JBrowse link
G Frrs1l ferric-chelate reductase 1-like multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRRS1L mRNA CTD PMID:27188386 NCBI chr 5:73,997,958...74,029,381
Ensembl chr 5:74,000,227...74,029,238
JBrowse link
G Fut9 fucosyltransferase 9 increases expression ISO belinostat results in increased expression of FUT9 mRNA CTD PMID:27188386 NCBI chr 5:40,032,855...40,237,591
Ensembl chr 5:40,032,855...40,237,591
JBrowse link
G Fzd5 frizzled class receptor 5 decreases expression ISO belinostat results in decreased expression of FZD5 mRNA CTD PMID:26272509 NCBI chr 9:71,443,784...71,445,541
Ensembl chr 9:71,443,588...71,445,739
JBrowse link
G Fzd7 frizzled class receptor 7 increases expression
multiple interactions
ISO belinostat results in increased expression of FZD7 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FZD7 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 9:66,305,731...66,308,550
Ensembl chr 9:66,305,731...66,308,550
JBrowse link
G Gabrb3 gamma-aminobutyric acid type A receptor subunit beta 3 increases expression
multiple interactions
ISO belinostat results in increased expression of GABRB3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRB3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:113,034,251...113,265,364
Ensembl chr 1:112,976,770...113,265,364
JBrowse link
G Gad1 glutamate decarboxylase 1 increases expression
multiple interactions
ISO belinostat results in increased expression of GAD1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAD1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 3:56,861,440...56,902,139
Ensembl chr 3:56,861,396...56,902,157
JBrowse link
G Gadd45a growth arrest and DNA-damage-inducible, alpha increases expression ISO belinostat results in increased expression of GADD45A mRNA; belinostat results in increased expression of GADD45A protein CTD PMID:29733868 NCBI chr 4:97,782,512...97,784,814
Ensembl chr 4:97,782,512...97,784,842
JBrowse link
G Galnt17 polypeptide N-acetylgalactosaminyltransferase 17 decreases expression ISO belinostat results in decreased expression of GALNT17 mRNA CTD PMID:27188386 NCBI chr12:28,381,879...29,268,457
Ensembl chr12:28,381,982...29,268,073
JBrowse link
G Galnt3 polypeptide N-acetylgalactosaminyltransferase 3 multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GALNT3 mRNA
belinostat results in increased expression of GALNT3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 3:52,174,469...52,212,395
Ensembl chr 3:52,175,547...52,212,412
JBrowse link
G Gap43 growth associated protein 43 increases expression
multiple interactions
ISO belinostat results in increased expression of GAP43 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAP43 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr11:58,624,198...58,717,916
Ensembl chr11:58,624,198...58,717,914
JBrowse link
G Gata3 GATA binding protein 3 increases expression
multiple interactions
ISO belinostat results in increased expression of GATA3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr17:72,419,752...72,452,043
Ensembl chr17:72,429,618...72,450,681
JBrowse link
G Gba3 glucosylceramidase beta 3 decreases expression ISO belinostat results in decreased expression of GBA3 mRNA CTD PMID:27188386 NCBI chr14:64,390,793...64,535,213
Ensembl chr14:64,390,793...64,535,170
JBrowse link
G Gbe1 1,4-alpha-glucan branching enzyme 1 decreases expression ISO belinostat results in decreased expression of GBE1 mRNA CTD PMID:27188386 NCBI chr11:7,210,169...7,485,895
Ensembl chr11:7,210,209...7,485,890
JBrowse link
G Gcat glycine C-acetyltransferase decreases expression ISO belinostat results in decreased expression of GCAT mRNA CTD PMID:27188386 NCBI chr 7:120,263,068...120,269,365
Ensembl chr 7:120,263,054...120,269,451
JBrowse link
G Gdap1l1 ganglioside-induced differentiation-associated protein 1-like 1 multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GDAP1L1 mRNA CTD PMID:27188386 NCBI chr 3:159,823,791...159,843,260
Ensembl chr 3:159,823,878...159,842,278
JBrowse link
G Gfra1 GDNF family receptor alpha 1 multiple interactions
decreases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GFRA1 mRNA
belinostat results in decreased expression of GFRA1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:279,203,046...279,572,789 JBrowse link
G Glb1l3 galactosidase, beta 1-like 3 increases expression
multiple interactions
ISO belinostat results in increased expression of GLB1L3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLB1L3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 8:27,865,452...27,907,726
Ensembl chr 8:27,865,350...27,907,911
JBrowse link
G Gldn gliomedin increases expression ISO belinostat results in increased expression of GLDN mRNA CTD PMID:27188386 NCBI chr 8:58,870,516...58,914,605
Ensembl chr 8:58,870,516...58,914,603
JBrowse link
G Glis3 GLIS family zinc finger 3 decreases expression ISO belinostat results in decreased expression of GLIS3 mRNA CTD PMID:26272509 NCBI chr 1:246,380,816...246,564,385
Ensembl chr 1:246,380,889...246,785,360
JBrowse link
G Glt8d2 glycosyltransferase 8 domain containing 2 decreases expression ISO belinostat results in decreased expression of GLT8D2 mRNA CTD PMID:27188386 NCBI chr 7:27,146,382...27,196,689
Ensembl chr 7:27,174,882...27,192,882
JBrowse link
G Gng11 G protein subunit gamma 11 increases expression ISO belinostat results in increased expression of GNG11 mRNA CTD PMID:26272509 NCBI chr 4:28,989,170...28,994,610
Ensembl chr 4:28,989,115...28,993,621
JBrowse link
G Gpc6 glypican 6 decreases expression
multiple interactions
ISO belinostat results in decreased expression of GPC6 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPC6 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr15:102,164,091...103,174,721
Ensembl chr15:102,164,751...103,170,847
JBrowse link
G Gpr143 G protein-coupled receptor 143 decreases expression ISO belinostat results in decreased expression of GPR143 mRNA CTD PMID:27188386 NCBI chr  X:23,668,363...23,693,162
Ensembl chr  X:23,668,363...23,693,162
JBrowse link
G Gpr27 G protein-coupled receptor 27 decreases expression ISO belinostat results in decreased expression of GPR27 mRNA CTD PMID:27188386 NCBI chr 4:132,137,793...132,138,926
Ensembl chr 4:132,137,793...132,138,926
JBrowse link
G Gpx7 glutathione peroxidase 7 decreases expression ISO belinostat results in decreased expression of GPX7 mRNA CTD PMID:27188386 NCBI chr 5:128,001,766...128,009,610
Ensembl chr 5:128,001,761...128,009,735
JBrowse link
G Grem1 gremlin 1, DAN family BMP antagonist increases expression
multiple interactions
ISO belinostat results in increased expression of GREM1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GREM1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 3:105,203,309...105,214,989
Ensembl chr 3:105,203,309...105,214,989
JBrowse link
G Grhl3 grainyhead-like transcription factor 3 increases expression
multiple interactions
ISO belinostat results in increased expression of GRHL3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 5:153,893,039...153,925,045
Ensembl chr 5:153,893,039...153,924,896
JBrowse link
G Gria3 glutamate ionotropic receptor AMPA type subunit 3 increases expression ISO belinostat results in increased expression of GRIA3 mRNA CTD PMID:27188386 NCBI chr  X:127,561,843...127,829,763
Ensembl chr  X:127,562,660...127,829,753
JBrowse link
G Grik1 glutamate ionotropic receptor kainate type subunit 1 increases expression ISO belinostat results in increased expression of GRIK1 mRNA CTD PMID:27188386 NCBI chr11:27,811,954...28,213,940
Ensembl chr11:27,811,957...27,971,359
JBrowse link
G Grk6 G protein-coupled receptor kinase 6 decreases expression ISO belinostat results in decreased expression of GRK6 mRNA CTD PMID:27188386 NCBI chr17:9,705,917...9,721,921
Ensembl chr17:9,703,453...9,721,574
JBrowse link
G Gsk3b glycogen synthase kinase 3 beta increases phosphorylation ISO belinostat results in increased phosphorylation of GSK3B protein CTD PMID:23671600 NCBI chr11:65,060,884...65,208,842
Ensembl chr11:65,066,235...65,209,268
JBrowse link
G H1f0 H1 histone family, member 0 increases expression ISO belinostat results in increased expression of H1-0 mRNA CTD PMID:19606018, PMID:27188386 NCBI chr 7:120,260,776...120,262,636 JBrowse link
G H1f10 H1.10 linker histone increases expression ISO belinostat results in increased expression of H1-10 mRNA CTD PMID:19606018 NCBI chr 4:119,889,016...119,892,661
Ensembl chr 4:119,889,371...119,889,949
JBrowse link
G H2bc12 H2B clustered histone 12 multiple interactions
decreases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC12 mRNA
belinostat results in decreased expression of H2BC12 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr17:44,527,421...44,527,801
Ensembl chr17:44,527,421...44,527,801
JBrowse link
G Hapln1 hyaluronan and proteoglycan link protein 1 multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAPLN1 mRNA
belinostat results in increased expression of HAPLN1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 2:18,354,542...18,419,077
Ensembl chr 2:18,354,542...18,419,071
JBrowse link
G Hapln4 hyaluronan and proteoglycan link protein 4 decreases expression ISO belinostat results in decreased expression of HAPLN4 mRNA CTD PMID:27188386 NCBI chr16:21,081,377...21,089,508
Ensembl chr16:21,081,377...21,089,508
JBrowse link
G Hbe1 hemoglobin subunit epsilon 1 decreases expression ISO belinostat results in decreased expression of HBE1 mRNA CTD PMID:27188386 NCBI chr 1:169,003,904...169,005,184
Ensembl chr 1:169,003,788...169,005,190
JBrowse link
G Heg1 heart development protein with EGF-like domains 1 decreases expression
multiple interactions
ISO belinostat results in decreased expression of HEG1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HEG1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr11:70,234,248...70,322,966
Ensembl chr11:70,236,888...70,322,690
JBrowse link
G Hes5 hes family bHLH transcription factor 5 multiple interactions
decreases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HES5 mRNA
belinostat results in decreased expression of HES5 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 5:172,364,421...172,365,188
Ensembl chr 5:172,364,421...172,365,188
JBrowse link
G Hesx1 HESX homeobox 1 decreases expression
multiple interactions
ISO belinostat results in decreased expression of HESX1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HESX1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr16:2,616,538...2,636,708
Ensembl chr16:2,634,603...2,636,708
JBrowse link
G Hey2 hes-related family bHLH transcription factor with YRPW motif 2 multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HEY2 mRNA
belinostat results in increased expression of HEY2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:29,191,170...29,201,257
Ensembl chr 1:29,191,192...29,201,531
JBrowse link
G Hgd homogentisate 1, 2-dioxygenase decreases expression ISO belinostat results in decreased expression of HGD mRNA CTD PMID:27188386 NCBI chr11:65,983,221...66,034,555
Ensembl chr11:65,983,221...66,034,573
JBrowse link
G Hhex hematopoietically expressed homeobox increases expression
multiple interactions
ISO belinostat results in increased expression of HHEX mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HHEX mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:256,101,994...256,107,581
Ensembl chr 1:256,101,903...256,107,649
JBrowse link
G Hist1h2bd histone cluster 1 H2B family member D decreases expression
multiple interactions
ISO belinostat results in decreased expression of H2BC5 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC5 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr17:44,833,924...44,834,305
Ensembl chr17:44,833,924...44,834,305
JBrowse link
G Hkdc1 hexokinase domain containing 1 decreases expression ISO belinostat results in decreased expression of HKDC1 mRNA CTD PMID:27188386 NCBI chr20:32,018,027...32,054,494 JBrowse link
G Hmx2 H6 family homeobox 2 increases expression
multiple interactions
ISO belinostat results in increased expression of HMX2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HMX2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:203,515,605...203,523,266
Ensembl chr 1:203,515,609...203,523,358
JBrowse link
G Homer2 homer scaffold protein 2 decreases expression ISO belinostat results in decreased expression of HOMER2 mRNA CTD PMID:26272509 NCBI chr 1:143,443,300...143,535,579
Ensembl chr 1:143,443,300...143,535,583
JBrowse link
G Hoxd3 homeo box D3 increases expression ISO belinostat results in increased expression of HOXD3 mRNA CTD PMID:27188386 NCBI chr 3:61,650,569...61,670,285
Ensembl chr 3:61,658,245...61,670,282
JBrowse link
G Hoxd4 homeo box D4 increases expression ISO belinostat results in increased expression of HOXD4 mRNA CTD PMID:27188386 NCBI chr 3:61,634,005...61,653,581
Ensembl chr 3:61,634,005...61,651,056
JBrowse link
G Hpdl 4-hydroxyphenylpyruvate dioxygenase-like increases expression
multiple interactions
ISO belinostat results in increased expression of HPDL mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HPDL mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 5:135,675,826...135,677,432
Ensembl chr 5:135,675,832...135,677,432
JBrowse link
G Hpgd 15-hydroxyprostaglandin dehydrogenase increases expression ISO belinostat results in increased expression of HPGD mRNA CTD PMID:26272509 NCBI chr16:37,457,134...37,495,758
Ensembl chr16:37,457,135...37,495,758
JBrowse link
G Hpx hemopexin decreases expression ISO belinostat results in decreased expression of HPX mRNA CTD PMID:27188386 NCBI chr 1:170,423,558...170,431,066
Ensembl chr 1:170,423,483...170,431,073
JBrowse link
G Hunk hormonally upregulated Neu-associated kinase decreases expression ISO belinostat results in decreased expression of HUNK mRNA CTD PMID:27188386 NCBI chr11:30,550,141...30,663,465
Ensembl chr11:30,550,141...30,663,465
JBrowse link
G Hus1 HUS1 checkpoint clamp component increases expression ISO belinostat results in increased expression of HUS1 mRNA CTD PMID:29733868 NCBI chr14:89,194,086...89,208,825
Ensembl chr14:89,194,092...89,208,825
JBrowse link
G Hyi hydroxypyruvate isomerase decreases expression ISO belinostat results in decreased expression of HYI mRNA CTD PMID:27188386 NCBI chr 5:137,189,440...137,192,125
Ensembl chr 5:137,189,473...137,192,240
JBrowse link
G Ice2 interactor of little elongation complex ELL subunit 2 increases expression ISO belinostat results in increased expression of ICE2 mRNA CTD PMID:27188386 NCBI chr 8:75,625,147...75,666,959
Ensembl chr 8:75,625,174...75,666,866
JBrowse link
G Id4 inhibitor of DNA binding 4, HLH protein increases expression
multiple interactions
ISO belinostat results in increased expression of ID4 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ID4 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr17:16,692,557...16,695,126
Ensembl chr17:16,692,557...16,695,126
JBrowse link
G Idh3a isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha increases expression
multiple interactions
ISO belinostat results in increased expression of IDH3A mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IDH3A mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 8:59,164,601...59,183,899
Ensembl chr 8:59,164,572...59,183,908
JBrowse link
G Idnk Idnk, gluconokinase decreases expression ISO belinostat results in decreased expression of IDNK mRNA CTD PMID:27188386 NCBI chr17:6,885,323...6,892,603
Ensembl chr17:6,885,221...6,892,497
JBrowse link
G Ido1 indoleamine 2,3-dioxygenase 1 multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IDO1 mRNA CTD PMID:27188386 NCBI chr16:72,216,326...72,228,098
Ensembl chr16:72,216,326...72,228,098
JBrowse link
G Ifit3 interferon-induced protein with tetratricopeptide repeats 3 decreases expression ISO belinostat results in decreased expression of IFIT3 mRNA CTD PMID:27188386 NCBI chr 1:252,906,234...252,911,377
Ensembl chr 1:252,906,234...252,911,382
JBrowse link
G Ifng interferon gamma multiple interactions ISO belinostat inhibits the reaction [IL15 protein results in increased expression of IFNG protein] CTD PMID:29301935 NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
JBrowse link
G Ifngr1 interferon gamma receptor 1 increases expression ISO belinostat results in increased expression of IFNGR1 mRNA CTD PMID:19606018 NCBI chr 1:15,062,380...15,080,815
Ensembl chr 1:15,062,432...15,080,907
JBrowse link
G Igf1 insulin-like growth factor 1 increases expression ISO belinostat results in increased expression of IGF1 mRNA CTD PMID:23671600 NCBI chr 7:28,412,123...28,491,815
Ensembl chr 7:28,412,198...28,486,609
JBrowse link
G Il15 interleukin 15 multiple interactions ISO belinostat inhibits the reaction [IL15 protein results in increased expression of IFNG protein] CTD PMID:29301935 NCBI chr19:23,542,606...23,624,366
Ensembl chr19:23,542,889...23,554,594
JBrowse link
G Il17d interleukin 17D decreases expression ISO belinostat results in decreased expression of IL17D mRNA CTD PMID:27188386 NCBI chr15:37,790,211...37,807,653
Ensembl chr15:37,790,141...37,807,660
JBrowse link
G Il17rb interleukin 17 receptor B decreases expression ISO belinostat results in decreased expression of IL17RB mRNA CTD PMID:27188386 NCBI chr16:6,064,287...6,077,978
Ensembl chr16:6,064,288...6,077,978
JBrowse link
G Il17rd interleukin 17 receptor D decreases expression
multiple interactions
ISO belinostat results in decreased expression of IL17RD mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IL17RD mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr16:2,670,471...2,737,271
Ensembl chr16:2,670,618...2,731,808
JBrowse link
G Il20rb interleukin 20 receptor subunit beta increases expression
multiple interactions
ISO belinostat results in increased expression of IL20RB mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IL20RB mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 8:108,745,906...108,778,561
Ensembl chr 8:108,747,204...108,777,717
JBrowse link
G Il4r interleukin 4 receptor decreases expression ISO belinostat results in decreased expression of IL4R mRNA CTD PMID:27188386 NCBI chr 1:196,942,343...196,967,221
Ensembl chr 1:196,942,364...196,967,220
JBrowse link
G Il6 interleukin 6 increases expression ISO belinostat results in increased expression of IL6 mRNA CTD PMID:23671600 NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
JBrowse link
G Impg1 interphotoreceptor matrix proteoglycan 1 increases expression ISO belinostat results in increased expression of IMPG1 mRNA CTD PMID:27188386 NCBI chr 8:87,733,374...87,879,958
Ensembl chr 8:87,733,545...87,879,888
JBrowse link
G Incenp inner centromere protein decreases expression ISO belinostat results in decreased expression of INCENP mRNA CTD PMID:19606018 NCBI chr 1:225,923,448...225,953,384
Ensembl chr 1:225,925,773...225,952,516
JBrowse link
G Inhba inhibin subunit beta A increases expression
multiple interactions
ISO belinostat results in increased expression of INHBA mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INHBA mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr17:51,894,869...51,919,998
Ensembl chr17:51,898,217...51,912,496
JBrowse link
G Inpp1 inositol polyphosphate-1-phosphatase decreases expression ISO belinostat results in decreased expression of INPP1 mRNA CTD PMID:27188386 NCBI chr 9:53,544,602...53,574,303
Ensembl chr 9:53,546,018...53,574,690
JBrowse link
G Irx1 iroquois homeobox 1 increases expression
multiple interactions
ISO belinostat results in increased expression of IRX1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:33,910,912...33,916,741
Ensembl chr 1:33,910,912...33,916,741
JBrowse link
G Irx2 iroquois homeobox 2 increases expression
multiple interactions
ISO belinostat results in increased expression of IRX2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:33,270,388...33,275,868
Ensembl chr 1:33,271,977...33,275,540
JBrowse link
G Itga2 integrin subunit alpha 2 increases expression ISO belinostat results in increased expression of ITGA2 mRNA CTD PMID:27188386 NCBI chr 2:46,996,904...47,097,011
Ensembl chr 2:47,000,323...47,096,961
JBrowse link
G Itga3 integrin subunit alpha 3 decreases expression ISO belinostat results in decreased expression of ITGA3 mRNA CTD PMID:27188386 NCBI chr10:82,855,841...82,887,755
Ensembl chr10:82,855,613...82,887,497
JBrowse link
G Itgb5 integrin subunit beta 5 decreases expression ISO belinostat results in decreased expression of ITGB5 mRNA CTD PMID:26272509 NCBI chr11:70,056,500...70,172,164
Ensembl chr11:70,056,500...70,172,372
JBrowse link
G Itm2a integral membrane protein 2A increases expression ISO belinostat results in increased expression of ITM2A mRNA CTD PMID:26272509 NCBI chr  X:78,490,872...78,496,814
Ensembl chr  X:78,490,866...78,496,847
JBrowse link
G Itpripl2 ITPRIP like 2 decreases expression ISO belinostat results in decreased expression of ITPRIPL2 mRNA CTD PMID:27188386 NCBI chr 1:188,140,853...188,142,748
Ensembl chr 1:188,141,113...188,142,721
JBrowse link
G Jazf1 JAZF zinc finger 1 multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JAZF1 mRNA CTD PMID:27188386 NCBI chr 4:82,834,181...83,141,430
Ensembl chr 4:82,836,260...83,137,527
JBrowse link
G Kansl1l KAT8 regulatory NSL complex subunit 1-like decreases expression ISO belinostat results in decreased expression of KANSL1L mRNA CTD PMID:27188386 NCBI chr 9:73,710,959...73,819,335
Ensembl chr 9:73,713,430...73,799,427
JBrowse link
G Kcnj13 potassium inwardly-rectifying channel, subfamily J, member 13 decreases expression
multiple interactions
ISO belinostat results in decreased expression of KCNJ13 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNJ13 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 9:94,486,719...94,495,333
Ensembl chr 9:94,487,224...94,495,333
JBrowse link
G Kcnj2 potassium inwardly-rectifying channel, subfamily J, member 2 decreases expression ISO belinostat results in decreased expression of KCNJ2 mRNA CTD PMID:27188386 NCBI chr10:99,429,337...99,442,520
Ensembl chr10:99,437,436...99,439,114
JBrowse link
G Kcnj3 potassium inwardly-rectifying channel, subfamily J, member 3 multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNJ3 mRNA CTD PMID:27188386 NCBI chr 3:41,019,898...41,181,070
Ensembl chr 3:41,019,898...41,181,070
JBrowse link
G Kdm4c lysine demethylase 4C increases expression ISO belinostat results in increased expression of KDM4C mRNA CTD PMID:27188386 NCBI chr 5:90,800,139...91,012,662
Ensembl chr 5:90,800,082...91,012,659
JBrowse link
G Kdr kinase insert domain receptor increases expression
multiple interactions
ISO belinostat results in increased expression of KDR mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KDR mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr14:34,727,677...34,787,127
Ensembl chr14:34,727,623...34,787,183
JBrowse link
G Keap1 Kelch-like ECH-associated protein 1 decreases expression ISO belinostat results in decreased expression of KEAP1 mRNA CTD PMID:19606018 NCBI chr 8:22,250,518...22,259,868
Ensembl chr 8:22,250,518...22,259,779
JBrowse link
G Klf5 Kruppel-like factor 5 increases expression
multiple interactions
ISO belinostat results in increased expression of KLF5 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF5 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr15:83,703,796...83,722,921
Ensembl chr15:83,703,791...83,722,921
JBrowse link
G Klf9 Kruppel-like factor 9 multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF9 mRNA CTD PMID:27188386 NCBI chr 1:240,908,483...240,933,198
Ensembl chr 1:240,908,483...240,933,198
JBrowse link
G Klhl18 kelch-like family member 18 increases expression ISO belinostat results in increased expression of KLHL18 mRNA CTD PMID:27188386 NCBI chr 8:118,668,809...118,737,672
Ensembl chr 8:118,671,312...118,696,187
JBrowse link
G Kpnb1 karyopherin subunit beta 1 decreases expression ISO belinostat results in decreased expression of KPNB1 mRNA CTD PMID:19606018 NCBI chr10:85,096,517...85,124,641
Ensembl chr10:85,093,841...85,124,644
JBrowse link
G Krt18 keratin 18 increases expression
multiple interactions
ISO belinostat results in increased expression of KRT18 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT18 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 7:143,629,455...143,633,131
Ensembl chr 7:143,629,455...143,633,131
JBrowse link
G Lactb lactamase, beta multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LACTB mRNA
belinostat results in increased expression of LACTB mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 8:72,750,174...72,766,307
Ensembl chr 8:72,750,171...72,766,389
JBrowse link
G Lama4 laminin subunit alpha 4 increases expression
multiple interactions
ISO belinostat results in increased expression of LAMA4 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMA4 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr20:44,060,715...44,201,966
Ensembl chr20:44,060,731...44,209,614
JBrowse link
G Lctl lactase-like decreases expression
multiple interactions
ISO belinostat results in decreased expression of LCTL mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LCTL mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 8:69,070,340...69,090,405
Ensembl chr 8:69,070,994...69,086,992
JBrowse link
G Lgi1 leucine-rich, glioma inactivated 1 increases expression ISO belinostat results in increased expression of LGI1 mRNA CTD PMID:26272509 NCBI chr 1:256,955,944...256,996,835
Ensembl chr 1:256,955,652...256,999,253
JBrowse link
G Lhx2 LIM homeobox 2 decreases expression
multiple interactions
ISO belinostat results in decreased expression of LHX2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LHX2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 3:22,628,674...22,658,447
Ensembl chr 3:22,640,545...22,658,446
JBrowse link
G Lhx8 LIM homeobox 8 increases expression
multiple interactions
ISO belinostat results in increased expression of LHX8 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LHX8 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 2:260,572,205...260,598,744
Ensembl chr 2:260,574,190...260,596,777
JBrowse link
G Lifr LIF receptor subunit alpha multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LIFR mRNA CTD PMID:27188386 NCBI chr 2:56,424,910...56,489,346
Ensembl chr 2:56,426,367...56,489,415
JBrowse link
G Limch1 LIM and calponin homology domains 1 decreases expression
multiple interactions
ISO belinostat results in decreased expression of LIMCH1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIMCH1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr14:42,760,363...43,072,976
Ensembl chr14:42,762,587...43,072,843
JBrowse link
G Lipg lipase G, endothelial type multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIPG mRNA CTD PMID:27188386 NCBI chr18:70,903,528...70,924,434
Ensembl chr18:70,901,710...70,924,708
JBrowse link
G Lman1 lectin, mannose-binding, 1 decreases expression ISO belinostat results in decreased expression of LMAN1 mRNA CTD PMID:26272509 NCBI chr18:61,683,377...61,707,344
Ensembl chr18:61,685,117...61,707,317
JBrowse link
G Lmo2 LIM domain only 2 decreases expression
multiple interactions
ISO belinostat results in decreased expression of LMO2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 3:93,909,156...93,931,888
Ensembl chr 3:93,909,156...93,931,871
JBrowse link
G Lmo3 LIM domain only 3 decreases expression
multiple interactions
ISO belinostat results in decreased expression of LMO3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 4:172,942,023...173,005,630
Ensembl chr 4:172,942,020...173,005,634
JBrowse link
G LOC100302372 hypothetical protein LOC100302372 increases expression
multiple interactions
ISO belinostat results in increased expression of KIAA0040 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIAA0040 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr13:77,784,516...77,822,333
Ensembl chr13:77,784,808...77,822,333
JBrowse link
G LOC100361016 oocyte specific homeobox 5-like increases expression
multiple interactions
ISO belinostat results in increased expression of VENTX mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VENTX mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr  X:93,064,417...93,067,181
Ensembl chr  X:93,064,686...93,065,675
JBrowse link
G LOC100362342 rCG47764-like decreases expression ISO belinostat results in decreased expression of C10ORF143 mRNA CTD PMID:27188386 NCBI chr 1:209,710,798...209,749,973
Ensembl chr 1:209,722,408...209,749,204
JBrowse link
G LOC100362814 hypothetical protein LOC100362814 decreases expression
multiple interactions
ISO belinostat results in decreased expression of KIAA1549L mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIAA1549L mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 3:94,058,546...94,334,805
Ensembl chr 3:94,064,234...94,182,714
JBrowse link
G LOC100912195 protein BEX1-like increases expression
multiple interactions
ISO belinostat results in increased expression of BEX5 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BEX5 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:116,565,779...116,567,283
Ensembl chr 1:116,565,790...116,567,189
JBrowse link
G LOC103690068 immortalization up-regulated protein-like multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C19ORF33 mRNA CTD PMID:27188386 NCBI chr 1:87,190,704...87,192,296
Ensembl chr 1:88,192,370...88,193,346
Ensembl chr 1:88,192,370...88,193,346
JBrowse link
G LOC103690190 histone H2A type 1-E multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2AC6 mRNA CTD PMID:27188386 NCBI chr17:44,747,686...44,748,229
Ensembl chr17:44,747,796...44,748,188
Ensembl chr17:44,747,796...44,748,188
JBrowse link
G Lpar1 lysophosphatidic acid receptor 1 decreases expression ISO belinostat results in decreased expression of LPAR1 mRNA CTD PMID:27188386 NCBI chr 5:75,557,038...75,678,067
Ensembl chr 5:75,557,042...75,676,584
JBrowse link
G Lpar6 lysophosphatidic acid receptor 6 increases expression ISO belinostat results in increased expression of LPAR6 mRNA CTD PMID:26272509 NCBI chr15:55,126,953...55,128,762
Ensembl chr15:55,126,953...55,128,761
JBrowse link
G Lrrc10b leucine rich repeat containing 10B decreases expression ISO belinostat results in decreased expression of LRRC10B mRNA CTD PMID:27188386 NCBI chr 1:226,500,692...226,501,920
Ensembl chr 1:226,500,692...226,501,920
JBrowse link
G Lrrc17 leucine rich repeat containing 17 increases expression ISO belinostat results in increased expression of LRRC17 mRNA CTD PMID:26272509 NCBI chr 4:10,108,184...10,138,652
Ensembl chr 4:10,108,192...10,138,652
JBrowse link
G Lrrc55 leucine rich repeat containing 55 multiple interactions
decreases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC55 mRNA
belinostat results in decreased expression of LRRC55 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 3:72,589,840...72,605,089
Ensembl chr 3:72,589,842...72,602,548
JBrowse link
G Lrrn3 leucine rich repeat neuronal 3 increases expression
multiple interactions
ISO belinostat results in increased expression of LRRN3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRN3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 6:61,374,328...61,405,195
Ensembl chr 6:61,374,328...61,405,195
JBrowse link
G LRRTM1 leucine rich repeat transmembrane neuronal 1 increases expression
multiple interactions
ISO belinostat results in increased expression of LRRTM1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRTM1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 4:108,300,927...108,316,373
Ensembl chr 4:108,301,129...108,316,373
JBrowse link
G Lyzl6 lysozyme-like 6 multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYZL6 mRNA
belinostat results in increased expression of LYZL6 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr10:91,694,547...91,701,428
Ensembl chr10:91,694,547...91,699,424
JBrowse link
G Macc1 MET transcriptional regulator MACC1 increases expression
multiple interactions
ISO belinostat results in increased expression of MACC1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MACC1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 6:147,315,232...147,392,530
Ensembl chr 6:147,315,328...147,394,269
JBrowse link
G Macroh2a1 macroH2A.1 histone multiple interactions
decreases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MACROH2A1 mRNA
belinostat results in decreased expression of MACROH2A1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr17:9,282,109...9,344,698
Ensembl chr17:9,282,675...9,344,678
JBrowse link
G Magi2 membrane associated guanylate kinase, WW and PDZ domain containing 2 increases expression
multiple interactions
ISO belinostat results in increased expression of MAGI2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAGI2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 4:10,995,241...12,472,423
Ensembl chr 4:10,995,234...11,610,518
JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta increases expression ISO belinostat results in increased expression of MAP1LC3B mRNA CTD PMID:19606018 NCBI chr19:53,635,449...53,643,970
Ensembl chr19:53,629,779...53,646,058
JBrowse link
G Map3k5 mitogen-activated protein kinase kinase kinase 5 decreases expression ISO belinostat results in decreased expression of MAP3K5 mRNA CTD PMID:27188386 NCBI chr 1:15,412,603...15,613,752
Ensembl chr 1:15,412,603...15,613,746
JBrowse link
G Map3k8 mitogen-activated protein kinase kinase kinase 8 increases expression ISO belinostat results in increased expression of MAP3K8 mRNA CTD PMID:27188386 NCBI chr17:56,109,403...56,129,925
Ensembl chr17:56,109,549...56,129,919
JBrowse link
G Map6 microtubule-associated protein 6 decreases expression
multiple interactions
ISO belinostat results in decreased expression of MAP6 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP6 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:164,225,776...164,292,094
Ensembl chr 1:164,225,934...164,292,093
JBrowse link
G Map7d2 MAP7 domain containing 2 decreases expression
multiple interactions
ISO belinostat results in decreased expression of MAP7D2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP7D2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr  X:38,400,578...38,467,825
Ensembl chr  X:38,397,261...38,468,360
JBrowse link
G Marveld1 MARVEL domain containing 1 decreases expression ISO belinostat results in decreased expression of MARVELD1 mRNA CTD PMID:27188386 NCBI chr 1:261,389,804...261,393,736
Ensembl chr 1:261,389,804...261,393,736
JBrowse link
G Mbnl3 muscleblind-like splicing regulator 3 increases expression
multiple interactions
ISO belinostat results in increased expression of MBNL3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MBNL3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr  X:138,378,674...138,473,365
Ensembl chr  X:138,384,912...138,435,391
JBrowse link
G Mchr1 melanin-concentrating hormone receptor 1 decreases expression ISO belinostat results in decreased expression of MCHR1 mRNA CTD PMID:27188386 NCBI chr 7:122,456,846...122,459,324
Ensembl chr 7:122,456,799...122,459,960
JBrowse link
G Mcm3 minichromosome maintenance complex component 3 decreases expression ISO belinostat results in decreased expression of MCM3 mRNA CTD PMID:19606018 NCBI chr 9:26,914,057...26,932,201
Ensembl chr 9:26,914,057...26,932,201
JBrowse link
G Mcm7 minichromosome maintenance complex component 7 decreases expression ISO belinostat results in decreased expression of MCM7 mRNA CTD PMID:19606018 NCBI chr12:19,306,615...19,313,877
Ensembl chr12:19,306,607...19,314,016
JBrowse link
G Mcoln3 mucolipin 3 increases expression
multiple interactions
ISO belinostat results in increased expression of MCOLN3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCOLN3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 2:251,930,532...252,007,722
Ensembl chr 2:251,983,339...252,007,560
JBrowse link
G Meox1 mesenchyme homeobox 1 increases expression
multiple interactions
ISO belinostat results in increased expression of MEOX1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEOX1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr10:89,797,011...89,817,009
Ensembl chr10:89,797,038...89,816,491
JBrowse link
G Mettl7b methyltransferase like 7B decreases expression ISO belinostat results in decreased expression of METTL7B mRNA CTD PMID:27188386 NCBI chr 7:3,383,876...3,386,522
Ensembl chr 7:3,383,879...3,386,522
JBrowse link
G Mfng MFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase decreases expression
multiple interactions
ISO belinostat results in decreased expression of MFNG mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFNG mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 7:119,978,981...119,996,824
Ensembl chr 7:119,978,983...119,996,824
JBrowse link
G Mgam maltase-glucoamylase decreases expression ISO belinostat results in decreased expression of MGAM mRNA CTD PMID:27188386 NCBI chr 4:69,018,592...69,114,027
Ensembl chr 4:68,849,033...68,996,961
JBrowse link
G Miat myocardial infarction associated transcript decreases expression
multiple interactions
ISO belinostat results in decreased expression of MIAT mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MIAT mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr12:50,447,251...50,461,859 JBrowse link
G Micalcl MICAL C-terminal like increases expression
multiple interactions
ISO belinostat results in increased expression of MICALCL mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MICALCL mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:177,183,436...177,232,674
Ensembl chr 1:177,183,209...177,232,691
JBrowse link
G Mlana melan-A decreases expression ISO belinostat results in decreased expression of MLANA mRNA CTD PMID:27188386 NCBI chr 1:247,869,756...247,883,558
Ensembl chr 1:247,869,756...247,884,442
JBrowse link
G Mlh1 mutL homolog 1 multiple interactions ISO belinostat promotes the reaction [decitabine results in increased expression of MLH1 protein] CTD PMID:19259094 NCBI chr 8:119,486,655...119,523,716
Ensembl chr 8:119,486,691...119,523,964
JBrowse link
G Mpg N-methylpurine-DNA glycosylase increases expression ISO belinostat results in increased expression of MPG mRNA CTD PMID:29733868 NCBI chr10:15,661,768...15,667,995
Ensembl chr10:15,661,608...15,668,022
JBrowse link
G Mpped2 metallophosphoesterase domain containing 2 decreases expression
multiple interactions
ISO belinostat results in decreased expression of MPPED2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MPPED2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 3:97,720,308...97,899,735
Ensembl chr 3:97,721,668...97,896,422
JBrowse link
G Msx1 msh homeobox 1 increases expression
multiple interactions
ISO belinostat results in increased expression of MSX1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr14:77,712,262...77,716,061
Ensembl chr14:77,712,240...77,716,059
JBrowse link
G Msx2 msh homeobox 2 multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX2 mRNA
belinostat results in increased expression of MSX2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr17:11,683,862...11,689,527
Ensembl chr17:11,683,862...11,689,527
JBrowse link
G Mthfs methenyltetrahydrofolate synthetase decreases expression ISO belinostat results in decreased expression of MTHFS mRNA CTD PMID:27188386 NCBI chr 8:96,564,877...96,614,386
Ensembl chr 8:96,564,877...96,614,348
JBrowse link
G Muc15 mucin 15, cell surface associated multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUC15 mRNA
belinostat results in increased expression of MUC15 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 3:101,895,363...101,912,979
Ensembl chr 3:101,899,068...101,912,919
JBrowse link
G Mylip myosin regulatory light chain interacting protein increases expression
multiple interactions
ISO belinostat results in increased expression of MYLIP mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYLIP mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr17:19,682,040...19,703,681
Ensembl chr17:19,682,040...19,703,681
JBrowse link
G Mylk myosin light chain kinase decreases expression ISO belinostat results in decreased expression of MYLK mRNA CTD PMID:26272509 NCBI chr11:69,013,060...69,260,039
Ensembl chr11:69,013,050...69,223,158
JBrowse link
G Myo3b myosin IIIB increases expression ISO belinostat results in increased expression of MYO3B mRNA CTD PMID:26272509 NCBI chr 3:56,355,433...56,717,740
Ensembl chr 3:56,355,431...56,584,547
JBrowse link
G Myof myoferlin increases expression ISO belinostat results in increased expression of MYOF mRNA CTD PMID:26272509 NCBI chr 1:256,585,410...256,734,727
Ensembl chr 1:256,585,410...256,734,730
JBrowse link
G Nanog Nanog homeobox increases expression
multiple interactions
ISO belinostat results in increased expression of NANOG mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NANOG mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 4:155,531,906...155,539,268
Ensembl chr 4:155,531,906...155,539,268
JBrowse link
G Nanos1 nanos C2HC-type zinc finger 1 decreases expression ISO belinostat results in decreased expression of NANOS1 mRNA CTD PMID:27188386 NCBI chr 1:282,134,676...282,140,370
Ensembl chr 1:282,134,981...282,135,772
JBrowse link
G Nav3 neuron navigator 3 increases expression ISO belinostat results in increased expression of NAV3 mRNA CTD PMID:26272509 NCBI chr 7:52,164,805...52,508,145
Ensembl chr 7:52,165,233...52,404,774
JBrowse link
G Ncald neurocalcin delta decreases expression
multiple interactions
ISO belinostat results in decreased expression of NCALD mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCALD mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 7:76,199,305...76,632,847
Ensembl chr 7:76,199,306...76,488,216
JBrowse link
G Ncan neurocan decreases expression ISO belinostat results in decreased expression of NCAN mRNA CTD PMID:26272509 NCBI chr16:21,050,243...21,076,707
Ensembl chr16:21,050,243...21,076,707
JBrowse link
G Ndp norrin cystine knot growth factor NDP decreases expression
multiple interactions
ISO belinostat results in decreased expression of NDP mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NDP mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr  X:6,791,090...6,815,586
Ensembl chr  X:6,791,136...6,815,583
Ensembl chr  X:6,791,136...6,815,583
JBrowse link
G Nefl neurofilament light increases expression ISO belinostat results in increased expression of NEFL mRNA CTD PMID:26272509 NCBI chr15:44,799,378...44,803,251
Ensembl chr15:44,799,334...44,804,574
JBrowse link
G Negr1 neuronal growth regulator 1 increases expression ISO belinostat results in increased expression of NEGR1 mRNA CTD PMID:27188386 NCBI chr 2:262,914,240...263,650,441
Ensembl chr 2:262,914,327...263,650,441
JBrowse link
G Nell2 neural EGFL like 2 decreases expression
multiple interactions
ISO belinostat results in decreased expression of NELL2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NELL2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 7:136,526,497...136,853,820
Ensembl chr 7:136,526,496...136,853,957
JBrowse link
G Neto2 neuropilin and tolloid like 2 decreases expression
multiple interactions
ISO belinostat results in decreased expression of NETO2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NETO2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr19:22,450,579...22,486,530
Ensembl chr19:22,450,030...22,486,531
JBrowse link
G Nexmif neurite extension and migration factor multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NEXMIF mRNA CTD PMID:27188386 NCBI chr  X:74,943,440...75,053,559
Ensembl chr  X:74,945,082...74,968,405
JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 multiple interactions
increases expression
ISO Bortezomib inhibits the reaction [belinostat results in increased expression of NFKB1 protein] CTD PMID:18223231 NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
JBrowse link
G Nfkbia NFKB inhibitor alpha increases expression
multiple interactions
ISO belinostat results in increased expression of NFKBIA protein
Bortezomib inhibits the reaction [belinostat results in increased expression of NFKBIA protein]
CTD PMID:18223231 NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
JBrowse link
G Ngef neuronal guanine nucleotide exchange factor multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NGEF mRNA CTD PMID:27188386 NCBI chr 9:94,569,286...94,601,852
Ensembl chr 9:94,569,286...94,601,852
JBrowse link
G Nipal2 NIPA-like domain containing 2 decreases expression ISO belinostat results in decreased expression of NIPAL2 mRNA CTD PMID:27188386 NCBI chr 7:73,339,706...73,450,262
Ensembl chr 7:73,339,706...73,450,262
JBrowse link
G Nlgn3 neuroligin 3 multiple interactions
decreases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NLGN3 mRNA
belinostat results in decreased expression of NLGN3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr  X:71,199,390...71,227,460
Ensembl chr  X:71,199,491...71,222,732
JBrowse link
G Nme8 NME/NM23 family member 8 multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NME8 mRNA
belinostat results in increased expression of NME8 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr17:47,300,932...47,368,543
Ensembl chr17:47,301,511...47,368,553
JBrowse link
G Nmi N-myc (and STAT) interactor increases expression
multiple interactions
ISO belinostat results in increased expression of NMI mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NMI mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 3:37,458,891...37,480,984
Ensembl chr 3:37,458,890...37,480,984
JBrowse link
G Noct nocturnin multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NOCT mRNA CTD PMID:27188386 NCBI chr 2:140,286,661...140,306,869
Ensembl chr 2:140,286,661...140,306,869
JBrowse link
G Nog noggin increases expression
multiple interactions
ISO belinostat results in increased expression of NOG mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADA mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADAM12 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRG1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRL3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANKS1B mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGEF37 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARNT2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of B3GNT5 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C14ORF39 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CALML4 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCKBR mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCND2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNKSR2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTN3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of COLGALT2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CRYBA4 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DAZL mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND1A mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DGKI mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EGF mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ELOVL2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHB2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM222A mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBLN1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBLN7 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXO43 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRRS1L mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GFRA1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPC6 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GSEC mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2AC6 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC12 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC5 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HEG1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HES5 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HESX1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HLA-DMB mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IL17RD mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNJ13 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNJ3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIAA1549L mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LCTL mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LHX2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIMCH1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LINC00894 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIPG mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC55 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MACROH2A1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP6 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP7D2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFNG mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MIAT mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MPPED2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCALD mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NDP mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NELL2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NETO2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NEXMIF mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NIFK-AS1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NLGN3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NOL4 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRXN2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NUCB2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OPLAH mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE10A mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PIEZO1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLD5 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLXNC1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PNMA2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRSS23 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAB33A mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAB3IP mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAX mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RBFOX3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ROBO2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RPH3AL mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RSL1D1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RTN1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of S1PR3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SDSL mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHC3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHISAL1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SIX3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC16A14 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC27A2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC9B2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMOC1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX6 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TNC mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TOX2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZEB1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACSM3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS15 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADCYAP1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANGPT1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANO3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2P2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP24 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARRB1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP8B1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAG2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAMBI mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BBS9 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BCL11A mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BEX5 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP5 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMPER mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BNC2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BORCS8 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BSPRY mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C11ORF96 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C19ORF33 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C8ORF34 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C8ORF34-AS1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CASP8 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCDC140 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCDC69 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCL26 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD24 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD9 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEP126 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEP85L mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHGA mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHODL mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHRM3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHRNA3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN7 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNMD mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNTN1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COBL mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL1A2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COMTD1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPNE4 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CR1L mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRIP1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRYBG1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTHRC1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXCL12 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXCL5 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DACT1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCC mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DEPDC7 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DEPTOR mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DHRS2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DIAPH2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DNER mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DPPA2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DPPA5 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EAF2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDN1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRA mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRB mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EFNA1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELMOD1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERVH48-1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ESRG mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ETS1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of F2RL1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FABP3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM162B mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM43A mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGF4 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FLT1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXD3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXH1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXO1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FZD7 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRB3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAD1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GALNT3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAP43 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GDAP1L1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLB1L3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GREM1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAPLN1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HEY2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HHEX mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HLA-DPB2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HMX2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HPDL mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ID4 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IDH3A mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IDO1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFI16 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFITM1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IL20RB mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INHBA mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITIH5 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JAZF1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KDR mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIAA0040 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF5 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF9 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT18 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LACTB mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMA4 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LHX8 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LIFR mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC00491 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC00698 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC01003 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRN3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRTM1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYZL6 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MACC1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAGI2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MBNL3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCOLN3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEOX1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MICALCL mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUC15 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYLIP mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NANOG mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NEAT1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NGEF mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NME8 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NMI mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NOCT mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPFFR2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPY mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NQO1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRP1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NWD2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OLFML3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX7 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH10 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH11Y mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDGFA mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDLIM1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDPN mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PHLDA2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIFO mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIPOX mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PKDCC mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G2A mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G4A mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLAAT3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLAU mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PODXL mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POLR3G mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POU2F3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POU5F1B mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POU5F1P3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POU5F1P4 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPARGC1B mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPIC mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPM1K mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP1R3B mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRDM14 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKACA mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRR15 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB3C mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RABGAP1L mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RARRES2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RHOB mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF144B mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF150 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF217 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RTP1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX1T1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A10 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SAT1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCG3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCGB3A2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCML1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCNN1A mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEMA3E mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEPTIN6 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SERPINB9 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SERPINI1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEZ6 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFMBT2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SGK3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC1A3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC35D3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC38A4 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC38A6 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLCO1B1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLCO4C1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLIT1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMARCA2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAI2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAP25 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOX8 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SP140L mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STMN2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SULT1C2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TACSTD2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TAFA2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TC2N mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2B mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2C mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFPI mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of THRB mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM30B mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM64 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFSF11 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNIK mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNN mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TPD52L1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRNP1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TTC29 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UGT3A1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UGT8 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of USP28 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UTF1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VASH2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VENTX mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VEPH1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WFDC2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT4 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZFP42 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZIC3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr10:76,811,759...76,813,386
Ensembl chr10:76,811,759...76,813,386
JBrowse link
G Nol4 nucleolar protein 4 decreases expression
multiple interactions
ISO belinostat results in decreased expression of NOL4 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NOL4 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr18:13,658,260...14,016,713
Ensembl chr18:13,658,271...14,016,713
JBrowse link
G Npffr2 neuropeptide FF receptor 2 increases expression
multiple interactions
ISO belinostat results in increased expression of NPFFR2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPFFR2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr14:20,148,485...20,193,577
Ensembl chr14:20,148,913...20,193,083
JBrowse link
G Npr3 natriuretic peptide receptor 3 increases expression ISO belinostat results in increased expression of NPR3 mRNA CTD PMID:26272509 NCBI chr 2:61,883,946...61,950,291
Ensembl chr 2:61,888,950...61,949,926
JBrowse link
G Npy neuropeptide Y increases expression
multiple interactions
ISO belinostat results in increased expression of NPY mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPY mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 4:79,557,856...79,565,059
Ensembl chr 4:79,557,854...79,565,097
JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NQO1 mRNA
belinostat results in increased expression of NQO1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
JBrowse link
G Nrp1 neuropilin 1 increases expression
multiple interactions
ISO belinostat results in increased expression of NRP1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRP1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr19:61,332,351...61,486,166
Ensembl chr19:61,332,351...61,485,858
JBrowse link
G Nrxn2 neurexin 2 decreases expression
multiple interactions
ISO belinostat results in decreased expression of NRXN2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRXN2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:221,792,191...221,908,047
Ensembl chr 1:221,792,221...221,908,049
JBrowse link
G Nsun7 NOP2/Sun RNA methyltransferase family member 7 decreases expression ISO belinostat results in decreased expression of NSUN7 mRNA CTD PMID:27188386 NCBI chr14:43,525,530...43,584,621
Ensembl chr14:43,527,579...43,584,343
JBrowse link
G Ntrk3 neurotrophic receptor tyrosine kinase 3 increases expression ISO belinostat results in increased expression of NTRK3 mRNA CTD PMID:27188386 NCBI chr 1:139,890,537...140,262,503
Ensembl chr 1:139,890,560...140,262,503
JBrowse link
G Nucb2 nucleobindin 2 decreases expression
multiple interactions
ISO belinostat results in decreased expression of NUCB2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NUCB2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:185,106,773...185,143,278
Ensembl chr 1:185,104,656...185,143,272
JBrowse link
G Nudt12 nudix hydrolase 12 increases expression ISO belinostat results in increased expression of NUDT12 mRNA CTD PMID:27188386 NCBI chr 9:105,680,603...105,693,374
Ensembl chr 9:105,680,670...105,693,357
JBrowse link
G Nwd2 NACHT and WD repeat domain containing 2 multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NWD2 mRNA CTD PMID:27188386 NCBI chr14:46,136,780...46,153,320
Ensembl chr14:46,136,786...46,153,212
JBrowse link
G Nxph2 neurexophilin 2 decreases expression ISO belinostat results in decreased expression of NXPH2 mRNA CTD PMID:26272509 NCBI chr 3:67,027...309,536
Ensembl chr 3:307,204...307,980
JBrowse link
G Ociad2 OCIA domain containing 2 decreases expression ISO belinostat results in decreased expression of OCIAD2 mRNA CTD PMID:27188386 NCBI chr14:37,432,999...37,449,425
Ensembl chr14:37,435,654...37,444,775
JBrowse link
G Odc1 ornithine decarboxylase 1 increases expression ISO belinostat results in increased expression of ODC1 mRNA CTD PMID:19606018 NCBI chr 6:42,852,529...42,859,142
Ensembl chr 6:42,852,683...42,859,927
JBrowse link
G Ogg1 8-oxoguanine DNA glycosylase decreases expression ISO belinostat results in decreased expression of OGG1 mRNA; belinostat results in decreased expression of OGG1 protein CTD PMID:29733868 NCBI chr 4:145,282,828...145,289,367
Ensembl chr 4:145,282,797...145,289,326
JBrowse link
G Olfm3 olfactomedin 3 increases expression ISO belinostat results in increased expression of OLFM3 mRNA CTD PMID:26272509 NCBI chr 2:217,779,983...218,005,710
Ensembl chr 2:217,963,456...218,005,509
JBrowse link
G Olfml3 olfactomedin-like 3 increases expression
multiple interactions
ISO belinostat results in increased expression of OLFML3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OLFML3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 2:206,219,419...206,222,248
Ensembl chr 2:206,219,419...206,222,248
JBrowse link
G Oplah 5-oxoprolinase (ATP-hydrolysing) multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OPLAH mRNA CTD PMID:27188386 NCBI chr 7:117,353,951...117,394,205
Ensembl chr 7:117,353,786...117,369,159
JBrowse link
G Pa2g4 proliferation-associated 2G4 decreases expression ISO belinostat results in decreased expression of PA2G4 mRNA CTD PMID:19606018 NCBI chr 7:2,979,587...2,987,055
Ensembl chr 7:2,979,588...2,987,055
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 increases cleavage
increases expression
multiple interactions
ISO belinostat results in increased cleavage of PARP1 protein
belinostat results in increased expression of PARP1 mRNA; belinostat results in increased expression of PARP1 protein
Bortezomib promotes the reaction [belinostat results in increased cleavage of PARP1 protein]
CTD PMID:18223231, PMID:29733868 NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
JBrowse link
G Parp9 poly (ADP-ribose) polymerase family, member 9 decreases expression ISO belinostat results in decreased expression of PARP9 mRNA CTD PMID:27188386 NCBI chr11:67,724,071...67,758,027
Ensembl chr11:67,724,076...67,756,799
JBrowse link
G Parvb parvin, beta decreases expression ISO belinostat results in decreased expression of PARVB mRNA CTD PMID:27188386 NCBI chr 7:125,189,827...125,275,977
Ensembl chr 7:125,189,827...125,277,689
JBrowse link
G Pax3 paired box 3 increases expression
multiple interactions
ISO belinostat results in increased expression of PAX3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 9:84,004,004...84,101,226
Ensembl chr 9:84,005,183...84,101,172
JBrowse link
G Pax7 paired box 7 increases expression
multiple interactions
ISO belinostat results in increased expression of PAX7 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX7 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 5:158,211,001...158,313,510
Ensembl chr 5:158,214,616...158,313,426
JBrowse link
G Pbx2 PBX homeobox 2 decreases expression ISO belinostat results in decreased expression of PBX2 mRNA CTD PMID:27188386 NCBI chr20:4,357,805...4,362,730
Ensembl chr20:4,357,733...4,362,682
JBrowse link
G Pcdh10 protocadherin 10 increases expression
multiple interactions
ISO belinostat results in increased expression of PCDH10 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH10 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 2:136,992,355...137,017,705
Ensembl chr 2:136,993,208...137,014,492
JBrowse link
G Pcdh7 protocadherin 7 decreases expression ISO belinostat results in decreased expression of PCDH7 mRNA CTD PMID:27188386 NCBI chr14:54,649,054...55,081,632
Ensembl chr14:55,072,200...55,081,551
JBrowse link
G Pcdh8 protocadherin 8 increases expression ISO belinostat results in increased expression of PCDH8 mRNA CTD PMID:26272509 NCBI chr15:62,196,469...62,201,498
Ensembl chr15:62,197,060...62,200,837
JBrowse link
G Pcsk9 proprotein convertase subtilisin/kexin type 9 decreases expression ISO belinostat results in decreased expression of PCSK9 mRNA CTD PMID:27188386 NCBI chr 5:126,031,368...126,053,726
Ensembl chr 5:126,031,368...126,053,726
JBrowse link
G Pde10a phosphodiesterase 10A decreases expression
multiple interactions
ISO belinostat results in decreased expression of PDE10A mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE10A mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:52,360,296...52,544,448
Ensembl chr 1:52,360,296...52,544,450
JBrowse link
G Pde7b phosphodiesterase 7B increases expression ISO belinostat results in increased expression of PDE7B mRNA CTD PMID:27188386 NCBI chr 1:15,889,845...16,203,909
Ensembl chr 1:15,893,533...16,203,909
JBrowse link
G Pdgfa platelet derived growth factor subunit A multiple interactions
increases expression
decreases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDGFA mRNA
belinostat results in increased expression of PDGFA mRNA
belinostat results in decreased expression of PDGFA mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr12:17,734,141...17,756,186
Ensembl chr12:17,734,133...17,755,285
JBrowse link
G Pdlim1 PDZ and LIM domain 1 multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDLIM1 mRNA
belinostat results in increased expression of PDLIM1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:259,308,326...259,357,006
Ensembl chr 1:259,308,296...259,357,056
JBrowse link
G Pdpn podoplanin increases expression
multiple interactions
ISO belinostat results in increased expression of PDPN mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDPN mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 5:161,947,137...161,981,441
Ensembl chr 5:161,947,137...161,981,441
JBrowse link
G Peg10 paternally expressed 10 increases expression ISO belinostat results in increased expression of PEG10 mRNA CTD PMID:19606018 NCBI chr 4:29,795,524...29,804,517 JBrowse link
G Pex13 peroxisomal biogenesis factor 13 increases expression ISO belinostat results in increased expression of PEX13 mRNA CTD PMID:27188386 NCBI chr14:108,394,299...108,411,994
Ensembl chr14:108,394,303...108,412,823
JBrowse link
G Phlda1 pleckstrin homology-like domain, family A, member 1 increases expression ISO belinostat results in increased expression of PHLDA1 mRNA CTD PMID:26272509 NCBI chr 7:54,247,460...54,249,664
Ensembl chr 7:54,247,460...54,249,664
JBrowse link
G Phlda2 pleckstrin homology-like domain, family A, member 2 increases expression
multiple interactions
ISO belinostat results in increased expression of PHLDA2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PHLDA2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:216,701,345...216,704,479
Ensembl chr 1:216,702,319...216,703,534
JBrowse link
G Piezo1 piezo-type mechanosensitive ion channel component 1 multiple interactions
decreases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PIEZO1 mRNA
belinostat results in decreased expression of PIEZO1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr19:55,305,494...55,367,680
Ensembl chr19:55,305,496...55,367,353
JBrowse link
G Pifo primary cilia formation increases expression
multiple interactions
ISO belinostat results in increased expression of PIFO mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIFO mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 2:208,616,592...208,633,961
Ensembl chr 2:208,616,589...208,633,945
JBrowse link
G Pim1 Pim-1 proto-oncogene, serine/threonine kinase increases expression ISO belinostat results in increased expression of PIM1 mRNA CTD PMID:26272509 NCBI chr20:8,165,423...8,169,557
Ensembl chr20:8,165,307...8,169,555
JBrowse link
G Pipox pipecolic acid and sarcosine oxidase increases expression
multiple interactions
ISO belinostat results in increased expression of PIPOX mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIPOX mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr10:64,951,986...64,964,865
Ensembl chr10:64,952,119...64,964,862
JBrowse link
G Pitx2 paired-like homeodomain 2 increases expression ISO belinostat results in increased expression of PITX2 mRNA CTD PMID:26272509 NCBI chr 2:233,602,732...233,621,059
Ensembl chr 2:233,602,732...233,621,129
JBrowse link
G Pkdcc protein kinase domain containing, cytoplasmic increases expression
multiple interactions
ISO belinostat results in increased expression of PKDCC mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PKDCC mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 6:6,427,657...6,436,974
Ensembl chr 6:6,427,657...6,436,974
JBrowse link
G Pla2g2a phospholipase A2 group IIA increases expression
multiple interactions
ISO belinostat results in increased expression of PLA2G2A mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G2A mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 5:157,282,650...157,285,295
Ensembl chr 5:157,282,669...157,285,328
JBrowse link
G Pla2g4a phospholipase A2 group IVA increases expression
multiple interactions
ISO belinostat results in increased expression of PLA2G4A mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G4A mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr13:67,062,252...67,206,688
Ensembl chr13:66,988,937...67,206,693
JBrowse link
G Plaat3 phospholipase A and acyltransferase 3 multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLAAT3 mRNA CTD PMID:27188386 NCBI chr 1:222,844,238...222,877,180
Ensembl chr 1:222,844,144...222,877,193
JBrowse link
G Plau plasminogen activator, urokinase increases expression
multiple interactions
ISO belinostat results in increased expression of PLAU mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLAU mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr15:3,644,296...3,650,765
Ensembl chr15:3,644,769...3,650,819
JBrowse link
G Plce1 phospholipase C, epsilon 1 decreases expression ISO belinostat results in decreased expression of PLCE1 mRNA CTD PMID:27188386 NCBI chr 1:257,156,023...257,465,440
Ensembl chr 1:257,157,264...257,466,064
JBrowse link
G Pld5 phospholipase D family, member 5 decreases expression
multiple interactions
ISO belinostat results in decreased expression of PLD5 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLD5 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr13:94,025,696...94,355,219
Ensembl chr13:94,025,369...94,355,219
JBrowse link
G Plekha2 pleckstrin homology domain containing A2 decreases expression ISO belinostat results in decreased expression of PLEKHA2 mRNA CTD PMID:27188386 NCBI chr16:71,725,649...71,784,432
Ensembl chr16:71,738,718...71,787,787
JBrowse link
G Plg plasminogen decreases expression ISO belinostat results in decreased expression of PLG mRNA CTD PMID:27188386 NCBI chr 1:48,521,828...48,563,895
Ensembl chr 1:48,521,772...48,563,776
JBrowse link
G Plpp5 phospholipid phosphatase 5 decreases expression ISO belinostat results in decreased expression of PLPP5 mRNA CTD PMID:27188386 NCBI chr16:71,121,175...71,125,794
Ensembl chr16:71,121,175...71,125,316
JBrowse link
G Plxnc1 plexin C1 decreases expression
multiple interactions
ISO belinostat results in decreased expression of PLXNC1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLXNC1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 7:35,848,083...36,000,969
Ensembl chr 7:35,850,398...36,000,906
JBrowse link
G Pnliprp2 pancreatic lipase related protein 2 decreases expression ISO belinostat results in decreased expression of PNLIPRP2 mRNA CTD PMID:27188386 NCBI chr 1:279,896,973...279,927,600
Ensembl chr 1:279,896,973...279,927,600
JBrowse link
G Pnma2 PNMA family member 2 decreases expression
multiple interactions
ISO belinostat results in decreased expression of PNMA2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PNMA2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr15:43,581,874...43,589,680
Ensembl chr15:43,582,020...43,589,680
JBrowse link
G Podxl podocalyxin-like increases expression
multiple interactions
ISO belinostat results in increased expression of PODXL mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PODXL mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 4:58,829,049...58,893,353
Ensembl chr 4:58,829,060...58,893,170
JBrowse link
G Polr3g RNA polymerase III subunit G increases expression
multiple interactions
ISO belinostat results in increased expression of POLR3G mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POLR3G mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 2:9,537,642...9,578,551
Ensembl chr 2:9,537,642...9,578,310
JBrowse link
G Pou2f3 POU class 2 homeobox 3 multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POU2F3 mRNA
belinostat results in increased expression of POU2F3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 8:47,412,063...47,495,042
Ensembl chr 8:47,410,220...47,494,982
JBrowse link
G Pou5f1 POU class 5 homeobox 1 increases expression ISO belinostat results in increased expression of POU5F1 mRNA CTD PMID:26272509 NCBI chr20:3,747,231...3,751,994
Ensembl chr20:3,747,221...3,751,994
JBrowse link
G Pou6f2 POU class 6 homeobox 2 increases expression ISO belinostat results in increased expression of POU6F2 mRNA CTD PMID:27188386 NCBI chr17:49,053,679...49,509,174 JBrowse link
G Ppargc1b PPARG coactivator 1 beta increases expression
multiple interactions
ISO belinostat results in increased expression of PPARGC1B mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPARGC1B mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr18:56,626,725...56,650,524
Ensembl chr18:56,626,712...56,728,968
JBrowse link
G Ppic peptidylprolyl isomerase C increases expression
multiple interactions
ISO belinostat results in increased expression of PPIC mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPIC mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr18:48,372,039...48,384,645
Ensembl chr18:48,372,041...48,384,645
JBrowse link
G Ppm1k protein phosphatase, Mg2+/Mn2+ dependent, 1K increases expression
multiple interactions
ISO belinostat results in increased expression of PPM1K mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPM1K mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 4:88,694,395...88,721,374
Ensembl chr 4:88,694,583...88,718,533
JBrowse link
G Ppp1r15a protein phosphatase 1, regulatory subunit 15A increases expression ISO belinostat results in increased expression of PPP1R15A mRNA CTD PMID:29733868 NCBI chr 1:101,511,899...101,515,043
Ensembl chr 1:101,511,901...101,514,974
JBrowse link
G Ppp1r3b protein phosphatase 1, regulatory subunit 3B increases expression
multiple interactions
ISO belinostat results in increased expression of PPP1R3B mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP1R3B mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr16:60,415,192...60,427,498
Ensembl chr16:60,415,229...60,427,474
JBrowse link
G Ppp4r4 protein phosphatase 4, regulatory subunit 4 increases expression ISO belinostat results in increased expression of PPP4R4 mRNA CTD PMID:27188386 NCBI chr 6:127,400,585...127,497,280
Ensembl chr 6:127,400,585...127,497,280
JBrowse link
G Prdm14 PR/SET domain 14 increases expression
multiple interactions
ISO belinostat results in increased expression of PRDM14 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRDM14 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 5:5,710,076...5,730,560
Ensembl chr 5:5,710,392...5,730,560
JBrowse link
G Prima1 proline rich membrane anchor 1 decreases expression ISO belinostat results in decreased expression of PRIMA1 mRNA CTD PMID:27188386 NCBI chr 6:127,075,954...127,127,985
Ensembl chr 6:127,075,954...127,127,413
JBrowse link
G Prkaca protein kinase cAMP-activated catalytic subunit alpha increases expression
multiple interactions
ISO belinostat results in increased expression of PRKACA mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKACA mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr19:25,095,089...25,118,869
Ensembl chr19:25,095,089...25,118,860
JBrowse link
G Prr15 proline rich 15 multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRR15 mRNA CTD PMID:27188386 NCBI chr 4:84,478,839...84,481,885
Ensembl chr 4:84,478,839...84,481,883
JBrowse link
G Prss23 serine protease 23 decreases expression
multiple interactions
ISO belinostat results in decreased expression of PRSS23 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRSS23 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:153,732,528...153,742,111
Ensembl chr 1:153,732,532...153,752,541
JBrowse link
G Pstk phosphoseryl-tRNA kinase decreases expression ISO belinostat results in decreased expression of PSTK mRNA CTD PMID:27188386 NCBI chr 1:201,950,148...201,960,563
Ensembl chr 1:201,950,144...201,965,488
JBrowse link
G Ptp4a3 protein tyrosine phosphatase 4A3 decreases expression ISO belinostat results in decreased expression of PTP4A3 mRNA CTD PMID:27188386 NCBI chr 7:114,969,699...115,002,902
Ensembl chr 7:114,997,103...115,002,902
JBrowse link
G Ptpn3 protein tyrosine phosphatase, non-receptor type 3 decreases expression ISO belinostat results in decreased expression of PTPN3 mRNA CTD PMID:27188386 NCBI chr 5:74,248,996...74,368,167
Ensembl chr 5:74,248,996...74,368,186
JBrowse link
G Ptpn5 protein tyrosine phosphatase, non-receptor type 5 decreases expression ISO belinostat results in decreased expression of PTPN5 mRNA CTD PMID:27188386 NCBI chr 1:103,197,918...103,258,309
Ensembl chr 1:103,197,915...103,256,823
JBrowse link
G Ptx3 pentraxin 3 decreases expression ISO belinostat results in decreased expression of PTX3 mRNA CTD PMID:26272509 NCBI chr 2:158,097,843...158,103,653
Ensembl chr 2:158,097,843...158,103,653
JBrowse link
G Pyroxd2 pyridine nucleotide-disulphide oxidoreductase domain 2 decreases expression ISO belinostat results in decreased expression of PYROXD2 mRNA CTD PMID:27188386 NCBI chr 1:261,961,164...261,987,029
Ensembl chr 1:261,961,379...261,986,759
JBrowse link
G Rab29 RAB29, member RAS oncogene family increases expression ISO belinostat results in increased expression of RAB29 mRNA CTD PMID:27188386 NCBI chr13:48,644,575...48,650,229
Ensembl chr13:48,644,604...48,650,220
JBrowse link
G Rab33a RAB33A, member RAS oncogene family multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAB33A mRNA CTD PMID:27188386 NCBI chr  X:135,348,799...135,360,204
Ensembl chr  X:135,348,436...135,360,203
JBrowse link
G Rab3c RAB3C, member RAS oncogene family increases expression
multiple interactions
ISO belinostat results in increased expression of RAB3C mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB3C mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 2:41,570,955...41,786,681
Ensembl chr 2:41,570,597...41,785,792
JBrowse link
G Rab3ip RAB3A interacting protein multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAB3IP mRNA CTD PMID:27188386 NCBI chr 7:59,927,486...59,971,518
Ensembl chr 7:59,928,426...59,957,232
JBrowse link
G Rabgap1l RAB GTPase activating protein 1-like increases expression
multiple interactions
ISO belinostat results in increased expression of RABGAP1L mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RABGAP1L mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr13:77,975,392...78,609,009
Ensembl chr13:78,011,047...78,609,045
JBrowse link
G Rac1 Rac family small GTPase 1 decreases expression ISO belinostat results in decreased expression of RAC1 mRNA CTD PMID:19606018 NCBI chr12:13,090,316...13,111,841
Ensembl chr12:13,090,172...13,111,873
JBrowse link
G Rad17 RAD17 checkpoint clamp loader component decreases expression ISO belinostat results in decreased expression of RAD17 mRNA CTD PMID:29733868 NCBI chr 2:30,634,353...30,664,618
Ensembl chr 2:30,634,354...30,664,163
JBrowse link
G Rad18 RAD18 E3 ubiquitin protein ligase decreases expression ISO belinostat results in decreased expression of RAD18 mRNA CTD PMID:29733868 NCBI chr 4:144,537,329...144,620,606
Ensembl chr 4:144,536,729...144,620,731
JBrowse link
G Rad51c RAD51 paralog C decreases expression ISO belinostat results in decreased expression of RAD51C mRNA; belinostat results in decreased expression of RAD51C protein CTD PMID:29733868 NCBI chr10:74,697,713...74,724,004
Ensembl chr10:74,697,716...74,724,472
JBrowse link
G Rad9a RAD9 checkpoint clamp component A decreases expression ISO belinostat results in decreased expression of RAD9A mRNA CTD PMID:29733868 NCBI chr 1:219,443,347...219,450,574
Ensembl chr 1:219,444,092...219,450,451
JBrowse link
G Ran RAN, member RAS oncogene family decreases expression ISO belinostat results in decreased expression of RAN mRNA CTD PMID:19606018 NCBI chr12:31,319,556...31,324,105
Ensembl chr12:31,320,624...31,323,810
JBrowse link
G Rarres1 retinoic acid receptor responder 1 decreases expression ISO belinostat results in decreased expression of RARRES1 mRNA CTD PMID:27188386 NCBI chr 2:164,650,722...164,684,982
Ensembl chr 2:164,650,722...164,684,985
JBrowse link
G Rarres2 retinoic acid receptor responder 2 increases expression
multiple interactions
ISO belinostat results in increased expression of RARRES2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RARRES2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 4:78,205,809...78,208,956
Ensembl chr 4:78,205,812...78,208,767
JBrowse link
G Rasef RAS and EF hand domain containing increases expression ISO belinostat results in increased expression of RASEF mRNA CTD PMID:26272509 NCBI chr 5:90,419,044...90,488,882
Ensembl chr 5:90,419,020...90,488,896
JBrowse link
G Rax retina and anterior neural fold homeobox decreases expression
multiple interactions
ISO belinostat results in decreased expression of RAX mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAX mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr18:61,638,352...61,642,056
Ensembl chr18:61,638,352...61,642,056
JBrowse link
G Rbfox3 RNA binding fox-1 homolog 3 decreases expression
multiple interactions
ISO belinostat results in decreased expression of RBFOX3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RBFOX3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr10:107,517,916...107,850,764
Ensembl chr10:107,516,995...107,539,658
JBrowse link
G Rcbtb2 RCC1 and BTB domain containing protein 2 decreases expression ISO belinostat results in decreased expression of RCBTB2 mRNA CTD PMID:27188386 NCBI chr15:55,029,388...55,074,728
Ensembl chr15:55,034,033...55,073,437
JBrowse link
G Rcc2 regulator of chromosome condensation 2 decreases expression ISO belinostat results in decreased expression of RCC2 mRNA CTD PMID:19606018 NCBI chr 5:159,220,531...159,236,313
Ensembl chr 5:159,220,979...159,234,320
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions
increases acetylation
ISO Bortezomib inhibits the reaction [belinostat results in increased acetylation of RELA protein] CTD PMID:18223231 NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
JBrowse link
G Reln reelin increases expression ISO belinostat results in increased expression of RELN mRNA CTD PMID:26272509 NCBI chr 4:9,347,533...9,774,257
Ensembl chr 4:9,347,528...9,773,670
JBrowse link
G Rev1 REV1, DNA directed polymerase decreases expression ISO belinostat results in decreased expression of REV1 mRNA CTD PMID:29733868 NCBI chr 9:44,714,137...44,786,330
Ensembl chr 9:44,714,386...44,786,041
JBrowse link
G RGD1359508 similar to protein C33A12.3 increases expression ISO belinostat results in increased expression of C4ORF33 mRNA CTD PMID:27188386 NCBI chr 2:128,675,786...128,738,215
Ensembl chr 2:128,675,814...128,700,640
JBrowse link
G RGD1564053 similar to hypothetical protein multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C8ORF34 mRNA
belinostat results in increased expression of C8ORF34 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 5:6,935,078...7,465,665
Ensembl chr 5:6,936,016...7,465,510
JBrowse link
G RGD1564664 similar to LOC387763 protein increases expression
multiple interactions
ISO belinostat results in increased expression of C11ORF96 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C11ORF96 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 3:82,854,779...82,856,171
Ensembl chr 3:82,854,777...82,856,171
JBrowse link
G Rhob ras homolog family member B increases expression
multiple interactions
ISO belinostat results in increased expression of RHOB mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RHOB mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 6:33,689,127...33,691,301
Ensembl chr 6:33,689,127...33,691,301
JBrowse link
G Rnf144b ring finger protein 144B increases expression
multiple interactions
ISO belinostat results in increased expression of RNF144B mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF144B mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr17:17,817,122...17,947,777
Ensembl chr17:17,817,100...17,947,777
JBrowse link
G Rnf150 ring finger protein 150 increases expression
multiple interactions
ISO belinostat results in increased expression of RNF150 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF150 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr19:24,044,210...24,264,508
Ensembl chr19:24,044,103...24,265,444
JBrowse link
G Rnf180 ring finger protein 180 decreases expression ISO belinostat results in decreased expression of RNF180 mRNA CTD PMID:27188386 NCBI chr 2:35,718,100...35,892,578
Ensembl chr 2:35,718,889...35,870,578
JBrowse link
G Rnf217 ring finger protein 217 multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF217 mRNA
belinostat results in increased expression of RNF217 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:28,301,960...28,391,582
Ensembl chr 1:28,301,922...28,390,837
JBrowse link
G Robo2 roundabout guidance receptor 2 decreases expression
multiple interactions
ISO belinostat results in decreased expression of ROBO2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ROBO2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr11:11,062,866...12,618,793
Ensembl chr11:11,062,790...11,585,765
JBrowse link
G Rph3al rabphilin 3A-like (without C2 domains) multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RPH3AL mRNA CTD PMID:27188386 NCBI chr10:63,989,556...64,140,584
Ensembl chr10:63,989,644...64,108,554
JBrowse link
G Rsl1d1 ribosomal L1 domain containing 1 multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RSL1D1 mRNA CTD PMID:27188386 NCBI chr10:4,375,329...4,387,195
Ensembl chr10:4,356,915...4,390,030
JBrowse link
G RT1-DMb RT1 class II, locus DMb decreases expression
multiple interactions
ISO belinostat results in decreased expression of HLA-DMB mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HLA-DMB mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr20:3,945,383...3,952,838
Ensembl chr20:5,227,045...5,234,290
JBrowse link
G RT1-Ha RT1 class II, locus Ha decreases expression ISO belinostat results in decreased expression of HLA-DPA1 mRNA CTD PMID:27188386 NCBI chr20:3,875,478...3,885,140
Ensembl chr20:3,875,706...3,881,461
JBrowse link
G Rtn1 reticulon 1 multiple interactions
decreases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RTN1 mRNA
belinostat results in decreased expression of RTN1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 6:94,951,016...95,177,477
Ensembl chr 6:94,951,020...95,061,174
JBrowse link
G Rtp1 receptor (chemosensory) transporter protein 1 multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RTP1 mRNA CTD PMID:27188386 NCBI chr11:80,823,989...80,826,505
Ensembl chr11:80,823,989...80,826,505
JBrowse link
G Runx1t1 RUNX1 partner transcriptional co-repressor 1 increases expression
multiple interactions
ISO belinostat results in increased expression of RUNX1T1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX1T1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 5:27,284,921...27,440,802
Ensembl chr 5:27,312,928...27,442,841
JBrowse link
G S100a10 S100 calcium binding protein A10 increases expression
multiple interactions
ISO belinostat results in increased expression of S100A10 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A10 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 2:193,892,589...193,901,236
Ensembl chr 2:193,892,589...193,901,236
JBrowse link
G S1pr3 sphingosine-1-phosphate receptor 3 decreases expression
multiple interactions
ISO belinostat results in decreased expression of S1PR3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of S1PR3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr17:13,799,383...13,812,877
Ensembl chr17:13,799,383...13,812,704
JBrowse link
G Sat1 spermidine/spermine N1-acetyl transferase 1 multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SAT1 mRNA
belinostat results in increased expression of SAT1 mRNA
CTD PMID:19606018, PMID:26272509, PMID:27188386 NCBI chr  X:43,626,480...43,629,767
Ensembl chr  X:43,625,169...43,629,765
JBrowse link
G Scg3 secretogranin III increases expression
multiple interactions
ISO belinostat results in increased expression of SCG3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCG3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 8:82,582,352...82,641,536
Ensembl chr 8:82,582,352...82,641,536
JBrowse link
G Scgb3a2 secretoglobin, family 3A, member 2 multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCGB3A2 mRNA
belinostat results in increased expression of SCGB3A2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr18:38,292,822...38,295,744
Ensembl chr18:38,292,701...38,295,831
JBrowse link
G Sclt1 sodium channel and clathrin linker 1 increases expression ISO belinostat results in increased expression of SCLT1 mRNA CTD PMID:27188386 NCBI chr 2:128,523,376...128,675,668
Ensembl chr 2:128,523,636...128,675,408
JBrowse link
G Scml1 Scm polycomb group protein like 1 multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCML1 mRNA
belinostat results in increased expression of SCML1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr  X:34,676,728...34,694,251 JBrowse link
G Scnn1a sodium channel epithelial 1 subunit alpha increases expression
multiple interactions
ISO belinostat results in increased expression of SCNN1A mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCNN1A mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 4:157,834,339...157,860,472
Ensembl chr 4:157,836,912...157,860,049
JBrowse link
G Sdsl serine dehydratase-like decreases expression
multiple interactions
ISO belinostat results in decreased expression of SDSL mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SDSL mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr12:41,636,994...41,647,205
Ensembl chr12:41,636,994...41,647,205
JBrowse link
G Sema3b semaphorin 3B decreases expression ISO belinostat results in decreased expression of SEMA3B mRNA CTD PMID:27188386 NCBI chr 8:116,353,791...116,362,655
Ensembl chr 8:116,354,073...116,361,343
JBrowse link
G Sema3c semaphorin 3C increases expression ISO belinostat results in increased expression of SEMA3C mRNA CTD PMID:26272509 NCBI chr 4:14,318,276...14,490,438
Ensembl chr 4:14,318,274...14,490,446
JBrowse link
G Sema3e semaphorin 3E increases expression
multiple interactions
ISO belinostat results in increased expression of SEMA3E mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEMA3E mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 4:17,314,745...17,594,659
Ensembl chr 4:17,272,511...17,594,598
JBrowse link
G Sema3f semaphorin 3F decreases expression ISO belinostat results in decreased expression of SEMA3F mRNA CTD PMID:27188386 NCBI chr 8:116,439,996...116,469,915
Ensembl chr 8:116,437,696...116,469,915
JBrowse link
G Sema6d semaphorin 6D decreases expression ISO belinostat results in decreased expression of SEMA6D mRNA CTD PMID:26272509 NCBI chr 3:116,899,906...116,958,059
Ensembl chr 3:116,899,878...116,958,050
JBrowse link
G Septin6 septin 6 increases expression
multiple interactions
ISO belinostat results in increased expression of SEPTIN6 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEPTIN6 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr  X:123,524,954...123,601,214
Ensembl chr  X:123,524,950...123,662,350
JBrowse link
G Serpina1 serpin family A member 1 decreases expression ISO belinostat results in decreased expression of SERPINA1 mRNA CTD PMID:27188386 NCBI chr 6:127,610,241...127,632,265
Ensembl chr 6:127,610,243...127,632,265
JBrowse link
G Serpina7 serpin family A member 7 decreases expression ISO belinostat results in decreased expression of SERPINA7 mRNA CTD PMID:27188386 NCBI chr  X:110,226,565...110,232,202
Ensembl chr  X:110,226,572...110,232,179
JBrowse link
G Serpinb1a serpin family B member 1A decreases expression ISO belinostat results in decreased expression of SERPINB1 mRNA CTD PMID:27188386 NCBI chr17:32,903,089...32,911,498
Ensembl chr17:32,904,119...32,911,495
JBrowse link
G Serpinb9 serpin family B member 9 increases expression
multiple interactions
ISO belinostat results in increased expression of SERPINB9 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SERPINB9 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr17:32,648,846...32,673,047
Ensembl chr17:32,650,441...32,661,865
JBrowse link
G Serpini1 serpin family I member 1 increases expression
multiple interactions
ISO belinostat results in increased expression of SERPINI1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SERPINI1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 2:174,013,058...174,111,693
Ensembl chr 2:174,013,288...174,111,752
JBrowse link
G Sesn3 sestrin 3 increases expression ISO belinostat results in increased expression of SESN3 mRNA CTD PMID:26272509 NCBI chr 8:12,823,060...12,878,749
Ensembl chr 8:12,823,155...12,872,705
JBrowse link
G Sez6 seizure related 6 homolog increases expression
multiple interactions
ISO belinostat results in increased expression of SEZ6 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEZ6 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr10:64,865,802...64,915,461
Ensembl chr10:64,865,805...64,915,148
JBrowse link
G Sfmbt2 Scm-like with four mbt domains 2 increases expression
multiple interactions
ISO belinostat results in increased expression of SFMBT2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFMBT2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr17:71,719,012...71,904,303
Ensembl chr17:71,723,620...71,897,972
JBrowse link
G Sgk3 serum/glucocorticoid regulated kinase family, member 3 increases expression
multiple interactions
ISO belinostat results in increased expression of SGK3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SGK3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 5:9,046,889...9,094,740
Ensembl chr 5:9,048,614...9,094,616
JBrowse link
G Shc3 SHC adaptor protein 3 multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHC3 mRNA CTD PMID:27188386 NCBI chr17:13,670,520...13,791,043
Ensembl chr17:13,670,520...13,791,043
JBrowse link
G Shisal1 shisa like 1 multiple interactions
decreases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHISAL1 mRNA
belinostat results in decreased expression of SHISAL1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 7:125,339,153...125,408,029
Ensembl chr 7:125,340,475...125,407,806
JBrowse link
G Shroom1 shroom family member 1 decreases expression ISO belinostat results in decreased expression of SHROOM1 mRNA CTD PMID:27188386 NCBI chr10:38,814,420...38,825,159
Ensembl chr10:38,814,799...38,824,673
JBrowse link
G Siae sialic acid acetylesterase increases expression ISO belinostat results in increased expression of SIAE mRNA CTD PMID:27188386 NCBI chr 8:40,078,269...40,113,514
Ensembl chr 8:40,078,269...40,113,514
JBrowse link
G Six3 SIX homeobox 3 decreases expression
multiple interactions
ISO belinostat results in decreased expression of SIX3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SIX3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 6:8,886,730...8,891,094
Ensembl chr 6:8,886,591...8,889,925
JBrowse link
G Six6os1 Six6 opposite strand transcript 1 multiple interactions
decreases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C14ORF39 mRNA
belinostat results in decreased expression of C14ORF39 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 6:95,761,718...95,797,314
Ensembl chr 6:95,762,332...95,796,502
JBrowse link
G Skap2 src kinase associated phosphoprotein 2 increases expression ISO belinostat results in increased expression of SKAP2 mRNA CTD PMID:27188386 NCBI chr 4:81,816,778...81,968,832
Ensembl chr 4:81,818,569...81,968,832
JBrowse link
G Slc16a14 solute carrier family 16, member 14 multiple interactions
decreases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC16A14 mRNA
belinostat results in decreased expression of SLC16A14 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 9:92,503,602...92,531,163
Ensembl chr 9:92,503,597...92,530,938
JBrowse link
G Slc1a3 solute carrier family 1 member 3 multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC1A3 mRNA CTD PMID:27188386 NCBI chr 2:57,860,881...57,935,363
Ensembl chr 2:57,860,834...57,935,363
JBrowse link
G Slc25a21 solute carrier family 25 member 21 decreases expression ISO belinostat results in decreased expression of SLC25A21 mRNA CTD PMID:27188386 NCBI chr 6:77,624,384...78,121,339
Ensembl chr 6:77,624,385...77,848,434
JBrowse link
G Slc27a2 solute carrier family 27 member 2 multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC27A2 mRNA CTD PMID:27188386 NCBI chr 3:119,014,620...119,052,531
Ensembl chr 3:119,014,620...119,052,531
JBrowse link
G Slc35d3 solute carrier family 35, member D3 increases expression
multiple interactions
ISO belinostat results in increased expression of SLC35D3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC35D3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:15,298,526...15,301,998
Ensembl chr 1:15,298,526...15,301,998
JBrowse link
G Slc35f3 solute carrier family 35, member F3 decreases expression ISO belinostat results in decreased expression of SLC35F3 mRNA CTD PMID:27188386 NCBI chr19:58,968,036...59,305,300
Ensembl chr19:59,186,673...59,304,832
JBrowse link
G Slc38a4 solute carrier family 38, member 4 increases expression
multiple interactions
ISO belinostat results in increased expression of SLC38A4 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC38A4 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 7:138,459,576...138,512,952
Ensembl chr 7:138,459,504...138,512,952
JBrowse link
G Slc38a6 solute carrier family 38, member 6 increases expression
multiple interactions
ISO belinostat results in increased expression of SLC38A6 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC38A6 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 6:96,171,756...96,241,512
Ensembl chr 6:96,171,756...96,241,096
JBrowse link
G Slc43a1 solute carrier family 43 member 1 increases expression ISO belinostat results in increased expression of SLC43A1 mRNA CTD PMID:26272509 NCBI chr 3:72,238,796...72,265,023
Ensembl chr 3:72,238,981...72,264,466
JBrowse link
G Slc44a3 solute carrier family 44, member 3 decreases expression ISO belinostat results in decreased expression of SLC44A3 mRNA CTD PMID:27188386 NCBI chr 2:225,038,261...225,112,859
Ensembl chr 2:225,038,582...225,107,283
JBrowse link
G Slc6a2 solute carrier family 6 member 2 increases expression ISO belinostat results in increased expression of SLC6A2 mRNA CTD PMID:27188386 NCBI chr19:15,391,682...15,431,274
Ensembl chr19:15,391,581...15,431,274
JBrowse link
G Slc7a11 solute carrier family 7 member 11 decreases expression ISO belinostat results in decreased expression of SLC7A11 mRNA CTD PMID:27188386 NCBI chr 2:139,453,774...139,528,479
Ensembl chr 2:139,453,774...139,528,162
JBrowse link
G Slc9b2 solute carrier family 9 member B2 decreases expression
multiple interactions
ISO belinostat results in decreased expression of SLC9B2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC9B2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 2:240,485,254...240,519,166
Ensembl chr 2:240,495,371...240,519,141
JBrowse link
G Slco4c1 solute carrier organic anion transporter family, member 4C1 increases expression
multiple interactions
ISO belinostat results in increased expression of SLCO4C1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLCO4C1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 9:104,301,935...104,350,262
Ensembl chr 9:104,299,277...104,350,308
JBrowse link
G Slfn4 schlafen family member 4 increases expression ISO belinostat results in increased expression of SLFN12 mRNA CTD PMID:27188386 NCBI chr10:70,411,686...70,435,162
Ensembl chr10:70,411,738...70,435,156
JBrowse link
G Slit1 slit guidance ligand 1 increases expression
multiple interactions
ISO belinostat results in increased expression of SLIT1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLIT1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:260,843,481...260,992,366
Ensembl chr 1:260,843,483...260,992,366
JBrowse link
G Slit2 slit guidance ligand 2 increases expression ISO belinostat results in increased expression of SLIT2 mRNA CTD PMID:26272509 NCBI chr14:66,831,848...67,171,491
Ensembl chr14:66,831,848...67,170,361
JBrowse link
G Smarca2 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 increases expression
multiple interactions
ISO belinostat results in increased expression of SMARCA2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMARCA2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:244,615,811...244,783,736
Ensembl chr 1:244,615,821...244,782,706
JBrowse link
G Smoc1 SPARC related modular calcium binding 1 decreases expression
multiple interactions
ISO belinostat results in decreased expression of SMOC1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMOC1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 6:104,718,403...104,879,611
Ensembl chr 6:104,718,512...104,877,980
JBrowse link
G Snai2 snail family transcriptional repressor 2 increases expression
multiple interactions
ISO belinostat results in increased expression of SNAI2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAI2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr11:90,404,421...90,406,730
Ensembl chr11:90,403,333...90,406,797
JBrowse link
G Snap25 synaptosome associated protein 25 increases expression
multiple interactions
ISO belinostat results in increased expression of SNAP25 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAP25 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 3:129,697,408...129,788,417
Ensembl chr 3:129,599,353...129,788,400
JBrowse link
G Snx10 sorting nexin 10 decreases expression ISO belinostat results in decreased expression of SNX10 mRNA CTD PMID:27188386 NCBI chr 4:81,311,490...81,375,248
Ensembl chr 4:81,311,490...81,374,158
JBrowse link
G Socs3 suppressor of cytokine signaling 3 decreases expression ISO belinostat results in decreased expression of SOCS3 mRNA CTD PMID:26272509 NCBI chr10:106,973,863...106,976,969
Ensembl chr10:106,975,178...106,976,040
JBrowse link
G Sox6 SRY-box transcription factor 6 multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX6 mRNA CTD PMID:27188386 NCBI chr 1:185,631,702...186,186,192
Ensembl chr 1:185,673,177...186,182,829
JBrowse link
G Sox8 SRY-box transcription factor 8 increases expression
multiple interactions
ISO belinostat results in increased expression of SOX8 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOX8 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr10:14,932,348...14,937,336
Ensembl chr10:14,932,348...14,937,336
JBrowse link
G Spink2 serine peptidase inhibitor, Kazal type 2 increases expression ISO belinostat results in increased expression of SPINK2 mRNA CTD PMID:26272509 NCBI chr14:33,247,278...33,253,913
Ensembl chr14:33,247,274...33,253,913
JBrowse link
G Spx spexin hormone decreases expression ISO belinostat results in decreased expression of SPX mRNA CTD PMID:27188386 NCBI chr 4:176,629,597...176,635,698
Ensembl chr 4:176,629,800...176,641,008
JBrowse link
G Sspn sarcospan decreases expression ISO belinostat results in decreased expression of SSPN mRNA CTD PMID:27188386 NCBI chr 4:180,291,389...180,325,799
Ensembl chr 4:180,291,389...180,324,408
JBrowse link
G Sst somatostatin increases expression ISO belinostat results in increased expression of SST mRNA CTD PMID:26272509 NCBI chr11:80,358,172...80,359,449
Ensembl chr11:80,358,211...80,359,444
JBrowse link
G Stc2 stanniocalcin 2 decreases expression ISO belinostat results in decreased expression of STC2 mRNA CTD PMID:27188386 NCBI chr10:16,542,909...16,552,675
Ensembl chr10:16,542,882...16,553,295
JBrowse link
G Stk32a serine/threonine kinase 32A decreases expression ISO belinostat results in decreased expression of STK32A mRNA CTD PMID:27188386 NCBI chr18:37,597,305...37,706,884
Ensembl chr18:37,597,156...37,710,306
JBrowse link
G Stmn2 stathmin 2 increases expression
multiple interactions
ISO belinostat results in increased expression of STMN2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STMN2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 2:95,424,251...95,471,900
Ensembl chr 2:95,424,251...95,472,115
JBrowse link
G Sult1c2a sulfotransferase family, cytosolic, 1C, member 2a increases expression
decreases expression
multiple interactions
ISO belinostat results in increased expression of SULT1C2 mRNA
belinostat results in decreased expression of SULT1C2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SULT1C2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 9:4,152,588...4,168,355
Ensembl chr 9:4,152,589...4,168,221
JBrowse link
G Sult2a1 sulfotransferase family 2A member 1 decreases expression ISO belinostat results in decreased expression of SULT2A1 mRNA CTD PMID:27188386 NCBI chr 1:76,558,721...76,614,315
Ensembl chr 1:76,252,329...76,780,230
JBrowse link
G Susd1 sushi domain containing 1 decreases expression ISO belinostat results in decreased expression of SUSD1 mRNA CTD PMID:27188386 NCBI chr 5:76,514,780...76,636,486
Ensembl chr 5:76,416,739...76,632,462
JBrowse link
G Synj2 synaptojanin 2 decreases expression ISO belinostat results in decreased expression of SYNJ2 mRNA CTD PMID:26272509 NCBI chr 1:46,835,922...46,932,544
Ensembl chr 1:46,835,971...46,932,529
JBrowse link
G Synm synemin decreases expression ISO belinostat results in decreased expression of SYNM mRNA CTD PMID:27188386 NCBI chr 1:128,692,112...128,722,048
Ensembl chr 1:128,692,112...128,722,048
JBrowse link
G Tacc1 transforming, acidic coiled-coil containing protein 1 increases expression ISO belinostat results in increased expression of TACC1 mRNA CTD PMID:19606018 NCBI chr16:71,596,970...71,681,126
Ensembl chr16:71,629,525...71,681,126
JBrowse link
G Tacstd2 tumor-associated calcium signal transducer 2 multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TACSTD2 mRNA
belinostat results in increased expression of TACSTD2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 4:98,341,187...98,342,887
Ensembl chr 4:98,341,188...98,342,887
JBrowse link
G Tafa2 TAFA chemokine like family member 2 increases expression
multiple interactions
ISO belinostat results in increased expression of TAFA2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TAFA2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 7:66,017,066...66,496,690
Ensembl chr 7:66,017,086...66,172,360
JBrowse link
G Taok3 TAO kinase 3 increases expression ISO belinostat results in increased expression of TAOK3 mRNA CTD PMID:26272509 NCBI chr12:45,037,951...45,116,593
Ensembl chr12:45,037,883...45,182,974
JBrowse link
G Tc2n tandem C2 domains, nuclear increases expression
multiple interactions
ISO belinostat results in increased expression of TC2N mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TC2N mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 6:125,437,767...125,601,408
Ensembl chr 6:125,437,775...125,590,049
JBrowse link
G Tcaim T cell activation inhibitor, mitochondrial decreases expression ISO belinostat results in decreased expression of TCAIM mRNA CTD PMID:27188386 NCBI chr 8:131,845,673...131,876,896
Ensembl chr 8:131,845,696...131,875,786
JBrowse link
G Tdgf1 teratocarcinoma-derived growth factor 1 increases expression ISO belinostat results in increased expression of TDGF1 mRNA CTD PMID:26272509 NCBI chr 8:119,215,266...119,220,909
Ensembl chr 8:119,215,495...119,219,232
JBrowse link
G Tfap2a transcription factor AP-2 alpha increases expression
multiple interactions
ISO belinostat results in increased expression of TFAP2A mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr17:24,653,342...24,670,457
Ensembl chr17:24,654,902...24,670,457
JBrowse link
G Tfap2b transcription factor AP-2 beta increases expression
multiple interactions
ISO belinostat results in increased expression of TFAP2B mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2B mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 9:25,410,669...25,440,568
Ensembl chr 9:25,410,669...25,440,411
JBrowse link
G Tfap2c transcription factor AP-2 gamma increases expression
multiple interactions
ISO belinostat results in increased expression of TFAP2C mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2C mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 3:170,550,314...170,558,197
Ensembl chr 3:170,550,314...170,558,194
JBrowse link
G Tff1 trefoil factor 1 decreases expression ISO belinostat results in decreased expression of TFF1 mRNA CTD PMID:27188386 NCBI chr20:9,892,124...9,895,984
Ensembl chr20:9,892,124...9,895,984
JBrowse link
G Tff2 trefoil factor 2 decreases expression ISO belinostat results in decreased expression of TFF2 mRNA CTD PMID:27188386 NCBI chr20:9,872,669...9,876,008
Ensembl chr20:9,872,680...9,876,008
JBrowse link
G Tfpi tissue factor pathway inhibitor increases expression
multiple interactions
ISO belinostat results in increased expression of TFPI mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFPI mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 3:71,852,738...71,902,127
Ensembl chr 3:71,852,744...71,893,618
JBrowse link
G Tgfb2 transforming growth factor, beta 2 increases expression ISO belinostat results in increased expression of TGFB2 mRNA CTD PMID:23671600 NCBI chr13:105,039,639...105,142,010
Ensembl chr13:105,039,853...105,141,030
JBrowse link
G Thrb thyroid hormone receptor beta increases expression
multiple interactions
ISO belinostat results in increased expression of THRB mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of THRB mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr15:8,890,578...9,239,815
Ensembl chr15:8,890,578...9,086,282
JBrowse link
G Timp3 TIMP metallopeptidase inhibitor 3 decreases expression ISO belinostat results in decreased expression of TIMP3 mRNA CTD PMID:26272509 NCBI chr 7:23,543,125...23,594,170
Ensembl chr 7:23,544,215...23,594,133
JBrowse link
G Tmem220 transmembrane protein 220 decreases expression ISO belinostat results in decreased expression of TMEM220 mRNA CTD PMID:27188386 NCBI chr10:53,570,980...53,579,994
Ensembl chr10:53,570,989...53,579,321
JBrowse link
G Tmem221 transmembrane protein 221 decreases expression ISO belinostat results in decreased expression of TMEM221 mRNA CTD PMID:26272509 NCBI chr16:19,984,368...19,992,507
Ensembl chr16:19,984,301...19,988,004
JBrowse link
G Tmem30b transmembrane protein 30B multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM30B mRNA
belinostat results in increased expression of TMEM30B mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 6:96,439,607...96,442,682
Ensembl chr 6:96,439,607...96,442,682
JBrowse link
G Tmem44 transmembrane protein 44 decreases expression ISO belinostat results in decreased expression of TMEM44 mRNA CTD PMID:27188386 NCBI chr11:73,737,323...73,774,149
Ensembl chr11:73,738,433...73,774,190
JBrowse link
G Tmem51 transmembrane protein 51 decreases expression ISO belinostat results in decreased expression of TMEM51 mRNA CTD PMID:27188386 NCBI chr 5:160,570,510...160,620,647
Ensembl chr 5:160,570,502...160,620,334
JBrowse link
G Tmem64 transmembrane protein 64 increases expression
multiple interactions
ISO belinostat results in increased expression of TMEM64 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM64 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 5:28,850,864...28,898,203
Ensembl chr 5:28,850,950...28,867,227
JBrowse link
G Tnc tenascin C decreases expression
multiple interactions
ISO belinostat results in decreased expression of TNC mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TNC mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 5:79,789,686...79,874,555
Ensembl chr 5:79,789,671...79,874,671
JBrowse link
G Tnfsf11 TNF superfamily member 11 multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFSF11 mRNA CTD PMID:27188386 NCBI chr15:60,482,527...60,512,704
Ensembl chr15:60,482,527...60,512,704
JBrowse link
G Tnik TRAF2 and NCK interacting kinase increases expression
multiple interactions
ISO belinostat results in increased expression of TNIK mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNIK mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 2:113,984,599...114,391,805
Ensembl chr 2:113,984,646...114,384,894
JBrowse link
G Tnn tenascin N multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNN mRNA CTD PMID:27188386 NCBI chr13:77,829,384...77,896,831
Ensembl chr13:77,829,382...77,896,697
JBrowse link
G Tox2 TOX high mobility group box family member 2 decreases expression
multiple interactions
ISO belinostat results in decreased expression of TOX2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TOX2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 3:159,569,329...159,694,756
Ensembl chr 3:159,569,363...159,694,756
JBrowse link
G Tp53 tumor protein p53 decreases expression ISO belinostat results in decreased expression of TP53 mRNA
belinostat results in decreased expression of TRP53 mRNA; belinostat results in decreased expression of TRP53 protein
CTD PMID:19606018, PMID:29733868 NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
JBrowse link
G Tpd52l1 TPD52 like 1 increases expression
multiple interactions
ISO belinostat results in increased expression of TPD52L1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TPD52L1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:28,454,949...28,578,736
Ensembl chr 1:28,454,966...28,576,553
JBrowse link
G Tpx2 TPX2, microtubule nucleation factor decreases expression ISO belinostat results in decreased expression of TPX2 mRNA CTD PMID:19606018 NCBI chr 3:148,327,965...148,370,187
Ensembl chr 3:148,327,965...148,370,187
JBrowse link
G Trib3 tribbles pseudokinase 3 decreases expression ISO belinostat results in decreased expression of TRIB3 mRNA CTD PMID:27188386 NCBI chr 3:147,814,056...147,819,650
Ensembl chr 3:147,813,473...147,819,571
JBrowse link
G Trnp1 TMF1-regulated nuclear protein 1 increases expression
multiple interactions
ISO belinostat results in increased expression of TRNP1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRNP1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 5:151,703,139...151,709,988
Ensembl chr 5:151,709,200...151,709,877
JBrowse link
G Ttc29 tetratricopeptide repeat domain 29 increases expression
multiple interactions
ISO belinostat results in increased expression of TTC29 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TTC29 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr19:33,205,576...33,424,955
Ensembl chr19:33,206,026...33,424,972
JBrowse link
G Tuba1a tubulin, alpha 1A affects expression ISO belinostat affects the expression of TUBA1A mRNA CTD PMID:27015953 NCBI chr 7:140,637,287...140,640,953
Ensembl chr 7:140,637,287...140,640,953
JBrowse link
G Tuft1 tuftelin 1 increases expression ISO belinostat results in increased expression of TUFT1 mRNA CTD PMID:19606018 NCBI chr 2:195,861,772...195,907,471
Ensembl chr 2:195,861,649...195,908,037
JBrowse link
G Twist1 twist family bHLH transcription factor 1 increases expression ISO belinostat results in increased expression of TWIST1 protein CTD PMID:23671600 NCBI chr 6:53,401,241...53,403,235
Ensembl chr 6:53,401,109...53,403,214
JBrowse link
G Txnrd3 thioredoxin reductase 3 decreases expression ISO belinostat results in decreased expression of TXNRD3 mRNA CTD PMID:27188386 NCBI chr 4:121,612,332...121,650,543
Ensembl chr 4:121,612,332...121,650,571
JBrowse link
G Tyms thymidylate synthetase decreases expression ISO belinostat results in decreased expression of TYMS mRNA CTD PMID:19606018 NCBI chr 9:121,918,875...121,931,564
Ensembl chr 9:121,918,947...121,931,564
JBrowse link
G Ugt1a1 UDP glucuronosyltransferase family 1 member A1 decreases glucuronidation
increases glucuronidation
ISO UGT1A1 gene polymorphism results in decreased glucuronidation of belinostat
UGT1A1 protein results in increased glucuronidation of belinostat
CTD PMID:23382909 NCBI chr 9:95,295,701...95,302,822
Ensembl chr 9:95,161,157...95,302,822
JBrowse link
G Ugt3a2 UDP glycosyltransferase 3 family, polypeptide A2 increases expression
multiple interactions
ISO belinostat results in increased expression of UGT3A1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UGT3A1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 2:58,666,337...58,682,212
Ensembl chr 2:58,668,157...58,681,747